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CHAPTER I 
INTRODUCTION 
Overview 
The development of a blood substitute is a significant medical need as blood 
shortages have become more common in this current decade and pathogens, such as 
HIV, pose risks for blood transfusions, limiting the amount of blood available in 
some parts of the world. Due to the world’s demand for blood, the development of 
hemoglobin-based oxygen carriers (HBOCs) has been an active area of research the 
last thirty years. An ideal oxygen carrier would deliver oxygen, be disease free, lack 
immunosuppressive effects, would not need blood typing, be available at a 
reasonable cost, and have minimal, if any, side effects (Ness and Cushing 2007; Sakai 
et al. 2000). 
The difficulties in producing an ideal oxygen carrier result from 
complications affiliated with the effects of HBOCs once administered during clinical 
trials. During the past decade, approaches to develop a HBOC utilizing polyethylene 
glycol (PEG) have been frequently used. Conjugation of PEG chains onto proteins has 
been a growing area of research due to the ability of PEGylated proteins to improve 
therapeutic potentials by camouflaging the proteins from the immune system. PEG 
also reduces glomerular filtration of the complexes from the body 
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(Bailon and Berthold 1998; Harris and Chess 2003; Roberts, Bentley, Harris 2002). 
PEGylation has been used in HBOCs to counteract some of the unfavorable side 
effects, such as low retention times of HBOCs in vivo, NO scavenging of the Hb, and 
the vasoconstrictive side-effects due to NO scavenging (Doherty et al. 1998; 
Muldoon et al. 1996).  Several PEG-HBOCs have reached clinical trials, but none have 
been approved for use in the United States. This review chapter outlines current 
statuses of the development of PEGylated Hb compounds and suggests some 
potential modifications that might improve their ability as potential HBOCs. 
Sites of PEGylation and Variations of PEG 
Attaching PEG chains onto a protein can be accomplished by an assortment 
of reactions. Different linking groups on the PEG molecule can achieve PEGylation at 
a variety of amino acid residues within the Hb tetramer. The first attempt at the 
PEGylation of Hb was done via urethane likages (Fig. 1) by Enzon resulting in 10 
copies of PEG-5K chains conjugated onto a single bovine Hb tetramer (Acharya et al. 
2011).  In order to simplify the PEGylation method and produce a more cost 
effective protocol, Extension Arm Facilitated (EAF) PEGylation was developed at 
Albert Einstein College of Medicine by Acharya and coworkers (Acharya and and 
Manjula 2006; Manjula et al. 2005). This form of PEGylation involves the thiolation 
of the tetramer using a heterobifunctional reagent to produce a thiol functional 
group that is later used to attach PEG chains onto the desired protein using a 
complementary functionalized PEG (Acharya et al. 2011; Acharya and and Manjula 
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2006; Manjula et al. 2005). EAF-PEG has little impact on the Hb tetramer stability of 
the PEG-Hb product, in direct contrast from direct PEGylation that destabilizes the 
quaternary structure of the PEG-Hb tetramer (Manjula et al. 2005). HexaPEGylated 
Hb’s generated by direct PEGylation exist primarily as Hb dimers, and the same was 
found with EAF-PEGylation (Hu et al. 2007; Li et al. 2008). Various types of EAF-
PEGylation techniques have emerged, including the use of propionamide, 
propylamine, and thiosuccinimido phenyl linkages (Fig 1.) (Li et al. 2008). This list is 
not exclusive since the production of a thiol functional group can be created in 
numerous ways, but Figure 1 includes some of the common techniques currently 
employed for Hb PEGylation. 
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Thiosuccinimido Phenyl Linkage [(SP-PEG5K)6-Hb] 
 
Figure 1.  Schematic representation of the linkages in the PEGylated Hbs generated 
by EAF PEGylation, acylation chemistry and reductive alkylation mediated 
PEGylation shown by Li et al.  The abbreviation “PEG” can be of varying lengths and 
a general schematic is listed first. For the EAF PEG linkers listed above, the linker 
type is first followed by its application (listed in parentheses or brackets)(Li et al. 
2008). 
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The common sites of PEGylation on Hb are on various Lys residues modified 
into thiol groups using Traut’s reagent. Li et al. determined the frequency of 
modification (Table 1). The modified lysines were: Lys-8 (), Lys-11 (), Lys-56 (), 
Lys-90 (), Lys-95 (), and Lys-132 () (Li et al. 2008). In addition, the free amino 
groups of the N-terminal Val residues of both chains were also PEGylated after 
reaction with Traut’s reagent (Li et al. 2008). PEGylation at these N-terminal sites 
destabilized the Hb tetramer (Hu et al. 2012). This may be attributed to the 
insertion of the PEG into the α dimer interface, dissociating the tetramer (Li et al. 
2008).  
Table 1. Identification of the sites of PEGylation in PEGylated Hb with corresponding 
P50 and Hill Coefficient (n) values as determined by Li et al. (Li et al. 2008). 
Residues Percent Modification in PEGylated Hbs (P50/n) 
HexaPEGylated Hb 
(10.8/1.9) 
OctaPEGylated Hb 
(8.5/2.1) 
DecaPEGylated Hb 
(8.0/2.0) 
Val-1(α) 48 80 100 
Val-1(β) 36 48 64 
Lys-8(β) 27 33 45 
Lys-11(α) 37 46 56 
Lys-56(α) 44 56 67 
Lys-90(α) 38 42 54 
Lys-95(β) 20 31 58 
Lys-132(β) 35 44 57 
*All PEGylated Hbs were modified via Propionyl-PEG 5kDa 
*P50 values are reported in mm Hg; n, Hill Coefficient 
 
In addition to the N-terminal Val residues, there are other sites on the Hb 
tetramer that should be avoided during PEGylation. Conjugation of PEG on Cys-93 
() has been studied to determine the effect on Hb functionality. Li and coworkers 
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demonstrated that Cys-93 () could be reversibly protected using 4,4-
dithiodipyridine (4-PDS) (Li et al. 2009). Consequently, EAF-PEG complexes were 
made with both protected and unprotected Hb’s (Figure 2) (Li et al. 2009; Wang et 
al. 2014). Compared to native Hb, PEGylation at the Cys-93 () residue produced a 
higher oxygen affinity, a lower Hill coefficient, an increased autoxidation rate, and a 
greater rate loss of the heme group (Hu et al. 2008; Li et al. 2009; Manjula et al. 
2003). Further oxygen binding studies by Li, Acharya, and colleagues, however, 
determined that avoiding PEGylation of Cys-93 () had a limited influence on 
oxygen affinity if the Hb was previously modified to keep it in a high oxygen affinity 
state or was unmodified entirely. The increased oxygen affinity observed in EAF-
PEG Hb can be a consequence of Hb PEGylation at other sites,  rather than 
modifications at Cys-93 (). However, modification of the Cys-93 () residue does 
result in a high oxygen affinity hemoglobin (Abraham, Phillips, Kennedy 1983; Li et 
al. 2009).   
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Figure 2. Schematic representation of the extension arm facilitated PEGylation of Hb 
with reversible protection of Cys-93 () performed by Li et al. It should be noted 
that PEGylation is shown on an alpha subunit of Hb but can occur on a subunit with 
an exposed Lys residue (Hu et al. 2012). 
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PEGylation on the Cys-93 () residues might be advantageous as it reduces 
the ability of Hb to scavenge NO in vivo. Kluger and co-workers found that PEGylated 
Hb created by this site specific modification produced NO at the heme faster than 
that of the native hemoglobin or non-PEGylated T state crosslinked hemoglobin 
(Lui, Dong, Kluger 2008). They proposed that the higher NO production was 
resultant from an increased stability of R state hemoglobin produced by PEGylation 
(Lui, Dong, Kluger 2008). The number of PEG chains attached to the hemoglobin 
tetramer did not appear to correlate with heme-nitrite reactivity so long as one PEG 
chain is conjugated specifically to the Cys-93 () residue. It was also found that 
heme-nitrite reactions within Hb conjugated with two PEG chains were comparable 
to Hb modified with six PEG chains (Lui, Dong, Kluger 2008). Lui et al. used a tetra-
functional crosslinker to link two hemoglobin tetramers together for stability, 
followed by PEGylation on the Cys-93 () residues on each hemoglobin tetramer. 
This resulting product was found to be non-hypertensive when administered into 
mouse models (Lui et al. 2012).  
Number of PEG Chains Attached to Hemoglobin and the Resulting Size 
Modification 
 The residues on which Hb can be PEGylated have been identified, but this 
does not imply that all the sites are PEGylated during every procedure. Depending 
on the reagent used, Hb can be PEGylated between two to ten sites (Li et al. 2008). 
Acharya and co-workers found that a twenty, forty, or eighty fold excess of 
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Propionyl PEG to Hb resulted in Hexa-, Octa-, or Deca-PEGylated Hb, respectively (Li 
et al. 2008). Enzon created this DecaPEGylated bovine Hb (Acharya et al. 2011), 
which was one of the first attempts at a PEG-Hb nanoparticle. Further studies and 
the development of thiolation-mediated EAF-PEGylation produced a Hexa-
PEGylated oxy-Hb. In doing so, it was found that this was an optimal PEGylation 
reaction since all of the Hb tetramers were fully PEGylated (Acharya, Manjula, Smith 
1996; Manjula et al. 2005). Table 1 shows the percentage of PEGylation at specific 
residues per Hb tetramer for the Hexa-, Octa-, or Deca-PEGylation species. The P50 
and n values for each PEGylated Hb (Table 1) show that while it is possible to 
produce a higher level of PEGylation on Hb, it is not necessary since the oxygen 
binding properties did not change significantly (Li et al. 2007).  
In addition to controlling the quantity of PEG chains attached to the protein, 
the length of the chains can also vary. Acharya and colleagues investigated PEG 
chains of weights in the 2-20 kDa range (Acharya et al. 2011; Hu et al. 2008; Li et al. 
2008). The most commonly used PEG weight is 5 kDa, but it has not been elucidated 
that it is more advantageous than the 3 kDa PEG for usage in a blood substitute 
(Vandegriff and Winslow 2009).  PEGylated proteins exhibit an apparent molecular 
mass that is higher than the molecular weights of the protein and PEG chains 
combined. This is a result of the PEG chains creating a hydration shell around the 
protein that increases the hydrodynamic volume (Portoeroe et al. 2008; Vandegriff 
et al. 2003). The hydrodynamic volumes of various HexaPEGylated-Hbs have been 
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determined by size exclusion chromatography (SEC) coupled with dynamic light 
scattering (DLS) (Li et al. 2008). Compared to native Hb (Table 2), PEGylated Hb 
showed a volume increase from eight to twelve fold, depending on the PEG 
decoration attached (Li et al. 2008). PEG chains create a shell around the Hb 
tetramer, increasing the particle volume (Figure 3). This is of relevance to blood 
substitutes because an increased volume should counteract the NO scavenging and 
reduce vasoconstriction (Palmer and Intaglietta 2014). Cooper proposed an 
increased hydrodynamic volume as a protection mechanism against NO scavenging, 
otherwise made permissible by a HBOC’s small size. A smaller total volume HBOC 
enables the tetramer to move closer to the arterial wall, where NO can be scavenged, 
leading to vasoconstriction (Cooper 2009). A total PEG mass of around 30 kDa may 
not suffice to counteract vasoactivity of a PEG-Hb polymer but a total mass of 
around 50 kDa may be sufficient to decrease NO scavenging (Rohlfs et al. 1998). 
Table 2. Influence of intramolecular α crosslinking on hydrodynamic volume, 
oxygen affinity and Hill Coefficients of PEGylated Hbs (Hu et al. 2007; Li et al. 2008). 
Sample Volume (nm3) P50 (mm Hg) Hill Coefficient (n) 
HbA 125 13.5 2.8 
αα-fumaryl Hb 125 30.5 2.4 
(Propionyl-PEG5K)6-Hb 860 10.0 1.9 
(Propionyl-PEG5K)6- αα-Hb 1375 18.0 1.5 
(Propyl-PEG5K)6-Hb 659 6.3 1.9 
(Propyl-PEG5K)6- αα-Hb 1204 16.0 1.5 
(SP-PEG5K)6-Hb 950 7.0 2.2 
(SP-PEG5K)6- αα-Hb 1047 9.9 1.7 
*P50 values are reported in mm Hg; n, Hill Coefficient 
11 
 
 
 
Figure 3. A pictorial representation of hexaPEGylated αα-fumaryl Hb. It has an 
internal protein shell with a molecular diameter of 6 nm and an outside shell with a 
molecular diameter of 14 nm. An intermediate protein hydration layer is 
sandwiched between the two shells. The thickness of this layer and the electrostatic 
interactions within this layer are expected to be dictated by the chemistry and site 
selectivity of the PEGylation. The two regions of the molecule differ significantly in 
the density. The outside PEG shell of medium density is filled loosely with PEG 
molecules (Li et al. 2008). 
 
Analysis of PEGylated Crosslinked Hemoglobin 
 One of the first attempts at creating a HBOC was to use stroma free Hb that 
had been crosslinked in order to maintain the Hb tetramer integrity. Unstable 
stroma free Hb can dissociate into -dimers that are small enough to be excreted 
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by the kidney (Bunn, Esham, Bull 1969; Chan et al. 2000). Bis(3,5 dibromosalicyl) 
fumarate (DBSF) crosslinks -amino groups of Lys821 and Lys822 under oxy 
conditions, producing a Hb with high oxygen affinity and increased stability (Fig. 4) 
(Walder et al. 1979; Walder, Walder, Arnone 1980; White and Olsen 1987; Yang and 
Olsen 1991; Zaugg et al. 1980). If this same reaction is done with deoxy-Hb, 
crosslinking occurs between Lys991 and Lys992 residues. This product exhibits a 
low oxygen affinity but increased stability (Fig. 4) (Chatterjee et al. 1986; Highsmith 
et al. 1997; Snyder et al. 1987; Tye et al. 1983; Yang and Olsen 1991). 
Crosslinking demonstrates an ability to stabilize the Hb tetramer. When 
PEGylation procedures were first developed, the stability of the Hb tetramer was a 
concern. Initially, PEG conjugation, not EAF-PEG conjugation, occupied the center of 
the Hb tetramer and displaced the water molecules within the central cavity 
between the Hb -dimers (Caccia et al. 2009; Hu et al. 2007; Hu et al. 2009; Hu et 
al. 2011). As a result, the Hb became less stable and split into two -dimers. This 
dissociative effect could be minimized by cross-linking the tetramer prior to 
PEGylation (White and Olsen 1987).   
From a structural point of view, it was suggested that upon crosslinking, 
stress originally present at the 11 interface induced by PEGylation was 
significantly reduced in comparison to non-crosslinked PEGylated hemoglobin (Hu 
et al. 2007). It was also noted that the heme environment was slightly perturbed 
when crosslinking and PEGylation were not used in combination. It is thought that 
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heme agitation in PEGylated -fumaryl crosslinked hemoglobin is significantly 
reduced as a result of an increased stability between the  interface (Hu et al. 
2007). Winslow, Acharya, and their respective laboratories found that (propyl-
PEG5K)6--Hb compared to (propyl-PEG5K)6-Hb exhibited a significantly 
enhanced molecular volume and a lower colloidal osmotic pressure (COP) (Hu et al. 
2007; Winslow 2003). This lowered COP makes it possible to use a HBOC solution of 
higher concentrations in clinical trials, which allows for a higher rate of oxygen 
delivery to tissues in the body that addressed an early limitation of PEGylated 
hemoglobins (Hu et al. 2007) . It has been found that PEGylation, in conjunction with 
crosslinking regardless of oxy or deoxy conditions, increases hemoglobin’s affinity 
for oxygen, creating a situation that favors oxygen delivery to hypoxic tissue. In 
summary, PEGylation and crosslinking should not be mutually exclusive techniques 
in the production of a HBOC. Rather, they should be used in conjunction to 
counteract some of the unfavorable side effects produced by the individual 
techniques. 
The Effects of PEGylation on Hemoglobin’s Oxygen Affinity/P50 and 
Cooperativity 
 A major challenge in HBOC production has been adjusting the oxygen binding 
properties. Within a red blood cell, a homeostatic environment allows hemoglobin 
to maintain its allosteric cooperativity. This allows the RBC to release its bound 
oxygen efficiently in peripheral tissues. A P50 of 26 mm Hg is established by pH 
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control inside the RBC along with the presence of 2,3-bisphosphoglycerate (2,3-
BPG). This results in Hb’s characteristic sigmoidal oxygen binding curve. A problem 
that arises is that most HBOC production utilizes stroma free Hb. Once the protein is 
extracted from the RBC, the P50 value drops from 26 mm Hg to around 13.5 mm Hg 
(Tables 2 and 3) (Hu et al. 2007; Li et al. 2008; Li et al. 2009; Meng et al. 2014). As a 
result, variations in crosslinking procedures, in conjunction with variations of EAF-
PEG chains conjugated to the protein, have been studied in attempts to circumvent 
the dramatic decrease in the P50 value. 
 Using DBSF as a crosslinker under oxy-conditions links the -monomers, 
favoring the R state conformation (Fig. 4). This reaction at the Lys-82() residues 
results in a Hb with higher oxygen affinity (Table 3). However, crosslinking with the 
same reagent under deoxy-conditions creates a lower oxygen affinity Hb (Table 3) 
by linking the  subunits, favoring the T state conformation (Figure 4). PEGylation 
always increases the oxygen affinity of Hb (Table 3), whether it is stroma free Hb,  
crosslinked Hb, or  crosslinked Hb (Hu et al. 2007; Li et al. 2008; Li et al. 2009; 
Meng et al. 2014). The type of EAF linker used does affect the oxygen affinity. For 
example,  crosslinked Hb modified with six propionyl PEG5K chains has a P50 of 
22.8 mm Hg whereas  crosslinked Hb modified with six propyl PEG5K chains has a 
P50 of 16.0 mm Hg (Highsmith et al. 1997; Hu et al. 2007). Protecting the Cys-93(β) 
residue allows production of a modified Hb tetramer with a lower oxygen affinity 
(Table 3). However, the effects of PEGylation on the tetramer still produce a higher 
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oxygen affinity Hb. This is resultant from the Cys-93(β) residue being exposed 
instead of buried in the Hb tetramer in the R state. Thus, any modifications on this 
site increase the oxygen affinity of the Hb tetramer by keeping it predominantly in 
the R state (Abraham, Phillips, Kennedy 1983). 
 
 
 
Figure 4. This is a standard crosslinking reaction that utilizes DBSF (a fumaryl 
crosslinker) to modify Hb. Under oxy-conditions ( crosslinking) crosslinking occurs 
between the two 99 lysine residues and under deoxy-conditions ( crosslinking) 
crosslinking occurs between the two 82 lysine residues. 
*It should be noted that crosslinking occurs within the central cavity of the Hb 
tetramer. 
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Along with altering the P50 values, crosslinking and PEGylation play a role in 
shifting the Hill coefficient (n). Hemoglobin, whether within RBCs or stroma free, 
has a Hill value around 2.8, but once modified, this value decreases, indicating a 
decrease in cooperativity (Table 3)(Hu et al. 2007; Li et al. 2008; Li et al. 2009; Meng 
et al. 2014). Upon PEGylation, the Hill coefficients of all forms of Hb decrease 
further. Crosslinking and PEGylation restrict the movement of the Hb tetramer, 
relative to unmodified Hb, decreasing its cooperativity. 
 
Table 3. Influence of intramolecular crosslinking (α, and ) and EAF PEG styles on 
oxygen affinity and Hill Coefficients (n) (Hu et al. 2007; Li et al. 2008; Meng et al. 
2014; Wang et al. 2014). 
PEGylated Hb Sample Oxygen Affinity 
P50 (mm Hg) Hill Coefficient (n) 
HbA 13.5 2.8 
αα-Hb 30.5 2.4 
ββ-Hb 6.3 2.1 
(Propyl-PEG5K)6-Hb 6.3 1.9 
(Propyl-PEG5K)6- αα-Hb 16.0 1.5 
(Propyl-PEG5K)6- ββ-Hb 5.9 1.9 
(Propionyl-PEG5K)6-Hb 10.0 1.8 
(Propionyl-PEG5K)6- αα-Hb 22.8 1.8 
(Urethane-PEG5K)6-Hb 8.0 2.0 
(Urethane-PEG5K)6-αα-Hb 23.3 2.1 
EAF-PEG-Hb without free Cys-93(β) 6.9 2.1 
EAF-PEG-Hb with free Cys-93(β) 8.5 2.0 
EAF-PEG-αα-Hb without free Cys-93(β) 9.9 1.7 
EAF-PEG-αα-Hb with free Cys-93(β) 18.5 1.7 
 
*αα-Hb=αα-fumaryl crosslinked Hb; ββ-Hb= ββ-intramolecular succinimidophenyl-
PEG2K crosslinked Hb 
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PEGylation and its Success: Hemospan, Functional Universal Red Blood Cells, 
and Polynitroxylated PEGylated Hemoglobin 
 Hemospan, also known as MP4, was created by Sangart via site-specific 
PEGylation chemistry that attached seven to eight 5 kDa maleimide-activated PEG 
chains to a single human  crosslinked hemoglobin tetramer (Vandegriff et al. 
2008). Hemospan injected into rat and mouse models along with humans was not 
shown to induce vasoconstriction, but unfortunately, its oxygen delivery was 
minimal as demonstrated by the reported P50 value of 5 mm Hg (Tsai et al. 2003; 
Vandegriff et al. 2003; Vandegriff and Winslow 2009). This low P50 value possesses 
some beneficial characteristics including a capacity to deliver oxygen to highly 
hypoxic tissues within humans. However, for overall oxygen delivery in vivo, the P50 
value (5 torr) is too low to use outside of oxygen delivery to dramatically hypoxic 
tissues Fortunately, MP4 does not induce vasoconstriction (by proxy, hypertension), 
and there was no gastrointestinal discomfort observed in subjects during Phase I 
and II clinical studies beginning in 2002 (Bjorkholm et al. 2005; Vandegriff and 
Winslow 2009). Furthermore, MP4 even progressed to Phase III clinical trials in 
Europe in attempts to assess its safety in controlled clinical orthopedic surgeries 
(Vandegriff and Winslow 2009).  
 In 2007, Acharya and colleagues employed PEGylation for the creation of a 
universal red blood cell derived from human blood (Nacharaju, Manjula, Acharya 
2007). Two PEGylation methods were used. In the first method, free amino groups 
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on red blood cell (RBC) membrane proteins were converted into exposed thiol 
groups using Traut’s reagent. These thiols were then modified with a maleimide-
PEG (Mal-Phe-PEG), with an optional second step of acylation chemistry-mediated 
PEGylation that attached a succinimidyl propionate-PEG (SPA-PEG) to amino groups 
on membrane proteins of the RBC (Nacharaju, Manjula, Acharya 2007). The first 
option for PEGylation yields a product that contains an extension arm produced 
from intermediate steps while the second option does not produce an extension arm 
between a membrane protein and the PEG chain. Differences were also seen 
between these two forms of PEGylated RBCs. It was found that the direct 
conjugation of PEG chains to RBC membrane proteins via SPA-PEG 5 kDa did not 
mask the D antigen (responsible for Rh +/- blood group) like the RBC that had EAF-
PEG modified proteins (Mal-Phe-PEG 5kD) (Nacharaju et al. 2005; Nacharaju, 
Manjula, Acharya 2007). Unfortunately, the small molecular size of the 5 kDa PEG 
chains was unable to mask the Rh system that accompanies blood typing unless an 
EAF PEGylation method is utilized. It is speculated that this phenomenon is 
permitted because Rh system antigens are multi-pass-transmembrane proteins with 
antigentic epitopes that are very close to the cell membrane and that even these 
small PEG chains are too bulky to react with the Rh antigen protein’s amino groups 
(Avent and Reid 2000; Bradley et al. 2002; Fisher and Armstrong 2002; Nacharaju, 
Manjula, Acharya 2007). In regards to masking the A antigen, it was found that it 
could only be achieved by subjecting the RBCs to a two phase PEGylation system by 
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first attaching 5 kDa PEG chains followed by the attachment of 20,000 kDa PEG 
chains (Nacharaju et al. 2005). The ABO blood type system antigens are 
carbohydrates located off membrane lipids and proteins and extend out into the 
solvent phase. Therefore, in order to mask them, bigger PEG chains were needed 
(King 1994; Reid and Mohandas 2004). The research of Acharya and coworkers 
showed that regardless of which antigen A, B, or D was meant to be masked by this 
two-step PEGylation procedure, it did not matter whether or not EAF PEGylation 
was utilized because antigen masking was achieved regardless of PEGylation 
method (Nacharaju et al. 2005; Nacharaju, Manjula, Acharya 2007). Only RBCs 
PEGylated via thiolation mediated PEGylation exhibited an increased oxygen affinity 
while those done with SPA-PEG had comparable oxygen affinities to that of 
unmodified erythrocytes (Nacharaju, Manjula, Acharya 2007). It was concluded that 
a two-phase PEGylation procedure, Mal-Phe-PEG 5 kDa followed by SPA-PEG 20 
kDa, would be most effective for masking A, B, and D antigens while having minimal 
influence on the RBCs oxygen binding affinity (dropping the P50 from 27.5 to 22.5) 
(Nacharaju, Manjula, Acharya 2007). 
 SynZyme Technologies created a novel HBOC, incorporating PEGylation and 
nitroxylation techniques to modify a Hb tetramer, called Polynitroxylated PEGylated 
Hemoglobin (PNPH) (Carleton, Hsia, Ma 2012). The product is a modified bovine Hb 
with 12-14 nitroxides and 8-10 PEG conjugations (Carleton, Hsia, Ma 2012; Lewis 
and Ross 2014; Shellington et al. 2011). The added nitroxides mimic the effects of 
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superoxide dismutase (SOD), present in a RBC, reducing oxidative stress by 
quenching reactive oxygen species (ROS) that are toxic to cells (Buehler et al. 2004; 
Lewis and Ross 2014). PNPH’s effects were examined in mice models to assess their 
neurotoxicity, and ability to attenuate fluid requirements in traumatic brain injury 
(TBI) with hemorrhagic shock (HS) (Brockman et al. 2013; Lewis and Ross 2014; 
Shellington et al. 2011). PNPH was found to not be cytotoxic to neurons in areas of 
the hippocampus and was found post TBI with HS that there was significantly lower 
brain edema in mice treated with PNPH compared to those treated with lactated 
Ringer’s (LR) solution (Brockman et al. 2013; Shellington et al. 2011). 
Unfortunately, PNPH has a high oxygen affinity (P50 10 mm Hg), indicating it will 
mainly deliver oxygen to severely hypoxic tissue (Lewis and Ross 2014; Shellington 
et al. 2011). The SOD-mimetic abilities of PNPH make it unique from all other 
previous PEG based HBOCs, however the low P50 is a major concern for delivering 
oxygen during HS or trauma situations.   
With these HBOCs, a clear disadvantage is that MP4 and universal RBC’s 
utilize human hemoglobin (or human RBCs) to create the final product, while MP4 
and PNPH have a very high oxygen affinity. While this may provide useful 
compounds that have potentially beneficial applications, all of these products do not 
address the need for a blood substitute independent of human blood donations. In 
addition, PEG RBCs would have the same storage problems as normal RBCs and 
while it is universal donor it is not a stable product.  
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Conclusions 
 An effective HBOC would be useful in trauma and other medical situations. 
Blood transfusions require disease free and properly type matched blood. This 
problem is exacerbated when blood donations are low, coupled with the short shelf 
life of donated blood. To counteract these complications, a PEGylated HBOC should 
be derived from non-human hemoglobin sources, universal for all types of blood, 
have a longer shelf life compared to donated whole blood, and be disease free. 
Review of the literature suggests that a larger molecular size HBOC, comparatively 
to the size of stroma free hemoglobin, is required to be successful in vivo. In 
addition, the HBOC should not dissociate into dimers, possess no nephrotoxicity, 
and should not scavenge NO from the endothelial tissue of the cardio vascular 
system. PEGylated hemoglobin has a larger hydrodynamic volume than native Hb 
and has shown to produce NO instead of removing it from living systems depending 
on the site of conjugation the PEG chains. Ideally, a PEGylated HBOC will be able to 
be lyophilized for longer storage. It has already been shown that PEGylation 
improves the stability of a PEGylated protein when it is reconstituted in liquid post 
lyophilization (Heller, Carpenter, Randolph 1999). In conclusion, a successful PEG 
based HBOC will have an increased size, contain extension arm facilitated PEG (EAF-
PEG) to not disrupt the Hb tetramer interface, be crosslinked to avoid Hb tetramer 
dissociation, and be derived from a non-human source. 
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CHAPTER II 
 
STATEMENT OF RESEARCH 
 
Blood transfusions require disease free and properly type matched blood. 
This becomes a problem when blood donations are at an all-time low coupled with 
the fact that the shelf life of donated blood is relatively short lived. Furthermore, 
there are areas of the world where clean blood is difficult to come by. To counteract 
these complications a blood substitute should be derived from non-human hemo-
globin sources that is universal for all types of blood, have a longer shelf life com-
pared to donated whole blood, and be disease free. If this problem were solved, it 
would relieve a myriad of problems within the current medical community and 
blood donation system. Review of the literature suggests that a larger molecular size 
HBOC, comparative to the size of stroma-free hemoglobin, is required to be success-
ful in vivo. In conjunction with the aforementioned characteristics, a HBOC needs to 
not dissociate into hemoglobin dimers, possess no nephrotoxicity, and it should not 
be able to scavenge NO from the endothelial tissue of the cardiovascular system. 
PEGylated hemoglobin has a larger hydrodynamic volume and is immunogenic 
compared to native hemoglobin. In the end, a successful PEG based HBOC will have 
an increased size, crosslinked to avoid tetramer dissociation, be unable to scavenge 
NO, and be able to deliver oxygen to tissues. 
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The first part of this novel research crosslinks (XL) bovine hemoglobin in a 
high oxygen affinity state ( XL-Hb). After crosslinking, the XL-Hb is covalently at-
tached to an eight arm maleimide PEG backbone via the Cys-93 () residue. This 
methodology covers a PEG back bone in multiple Hb tetramers. This methodology is 
the reverse of traditional PEGyaltion and thus has been called “inside-out” PEGyla-
tion. The hemoglobin is extracted from whole bovine blood, so there is no need for 
human donations, and the crosslinking procedure will prevent the hemoglobin from 
dissociating into dimers in vivo. In addition, the site of conjugation on the Cys-93 () 
has been found to be favorable in reducing NO scavenging from endothelial tissue 
making it an ideal site for conjugation of the PEG backbone. The second part of the 
research crosslinks bovine Hb in a lower oxygen affinity state ( XL-Hb). After, the 
XL-Hb is activated with an alkyne by an NHS ester. The alkyne is able to react with 
an eight arm azide PEG by strain promoted azide-alkyne click chemistry. This form 
of inside-out PEGylation yields a lower oxygen affinity Hb polymer compared to the 
previously mentioned methodology. Finally the large size of the polymers should 
assist in reducing its ability to scavenge NO. 
A universal HBOC for every medical situation does not have to exist. Varia-
tions amongst HBOCs oxygen affinity would allow medical providers to prescribe a 
proper HBOC for a given circumstance. Based on these considerations I have pro-
duced a high and a low affinity PEG XL-Hb polymer that are intended to be used in 
lieu of blood transfusions. 
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CHAPTER III 
“INSIDE-OUT” PEGYLATION OF BOVINE -CROSSLINKED HEMOGLOBIN 
Chapter Introduction 
Human blood transfusions are the only viable way to rapidly replace lost 
blood in a patient while delivering oxygen to tissues.  Transfusions have limitations 
due to risks affiliated with blood borne pathogens, the limited shelf life of donated 
blood, immunogenic responses, hemolytic transfusion reactions, and a dependence 
on human donation (Jahr et al. 2011). Stroma-free hemoglobin (Hb) is not a viable 
replacement because of tetramer dissociation in circulation, leading to rapid 
filtration by the kidneys and subsequent nephrotoxicity. It is also capable of 
scavenging nitric oxide which induces vasoconstriction leading to increased 
peripheral vascular resistance and subsequent organ dysfunction (Doherty et al. 
1998; Muldoon et al. 1996; Reid 2003). These problems have shown the need for a 
viable alternative. An ideal hemoglobin-based oxygen carrier (HBOC) would 
efficiently deliver oxygen to tissues while being pathogen free, universal for all 
blood types, non-immunogenic, and available at a minimal cost while possessing a 
long shelf life with minimal refrigeration (Estep et al. 2008; Ness and Cushing 2007; 
Reid 2003; Sakai et al. 2000). While crosslinking (XL) the Hb tetramer prevents 
dissociation, tetramers solely modified by crosslinking failed as HBOCs due to 
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damage to the vascular tissue and NO scavenging (Ness and Cushing 2007; Reid 
2003; Sakai et al. 2000).  
To counteract these problems previous HBOC design has produced bis-
tetrameric Hb polymers, liposome encapsulated Hb nanoparticles, Hb 
microparticles, and polyethylene glycol (PEG) Hb conjugates (Agashe and Awasthi 
2009; Bradley et al. 2002; Lui et al. 2012; Singh et al. 2015; Xiong et al. 2012). 
Recent reviews have shown that conjugation of PEG to Hb has been one of the more 
successful methods thus far (Jahr, Akha, Holtby 2012; Palmer and Intaglietta 2014).  
Protein PEGylation has been shown to improve therapeutic potential by 
camouflaging the proteins from the immune system and reduce glomerular 
filtration from the body (Bailon and Berthold 1998; Harris and Chess 2003; Roberts, 
Bentley, Harris 2002). Several approaches exist to PEGylate Hb. Variations have 
been made in the size of the PEG chains, the number of PEG chains conjugated to a 
single Hb tetramer, the sites of PEGylation, the methods of conjugating PEG chains 
to Hb, and the crosslink status of the Hb (Hu et al. 2007; Li et al. 2008; Li et al. 2009). 
Acharya and coworkers found that when six PEG chains were conjugated to a single 
Hb tetramer, the oxygen affinity of the Hb polymer increased in comparison to 
native Hb (Li et al. 2007). It was previously proposed by Winslow and co-workers 
(Rohlfs et al. 1998) that a total PEG mass around 50 kDa to one Hb molecule would 
be sufficient to counteract vasoactivity of Hb in the bloodstream. Moreover, other 
larger hemoglobin complexes, such as the zero-length crosslinked product by Bucci 
and co-workers (Oxy Vita) (Matheson et al. 2002), are not vasoactive (Harrington 
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and Wollocko 2011; Martini et al. 2006; Palmer and Intaglietta 2014). From these 
studies one concludes that a way to counteract vasoactivity is to produce a polymer 
with a large size or hydrodynamic volume (Palmer 2006; Palmer and Intaglietta 
2014). A polymer of such a size can be produced by conjugating PEG onto the Hb 
tetramer and will stay in the center of the blood flow preventing deleterious 
endothelial NO scavenging (Alayash 2004; Palmer 2006; Palmer and Intaglietta 
2014).  
While most PEG chains have been attached to exposed Lys residues on the 
Hb tetramer through NHS-Ester amidation, it is also possible to conjugate PEG 
chains onto the Cys 93 residue (Li et al. 2008).  This modification increased the 
oxygen affinity of hemoglobin but allowed for oxygen deliver to ischemic tissues 
(Abraham, Phillips, Kennedy 1983; Li et al. 2009). In addition, multiple PEG chains 
generate a hydration shell around a single Hb tetramer in current PEGylated HBOCs, 
increasing the hydrodynamic volume. In this chapter the reverse approach has been 
utilized with a PEG polymer to which multiple Hb tetramers are attached by click 
chemistry. Click chemistry is defined as a reaction that has a large thermodynamic 
driving force that favors a single product. The click chemistry used to produce the 
large Hb polymers is the thiol-maleimide reaction. A PEG backbone with eight arms, 
each containing a terminal maleimide functional group (Mal-PEG), is capable of 
reacting with Hb tetramers via the Cys 93 residues. Therefore, the maximum 
number of Hb tetramers that may be conjugated to a single PEG backbone is eight. 
However, it is more likely that once the Mal-PEG reacts with one Cys 93, it will then 
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react with the other exposed Cys 93 in the same tetramer. Thus, one would expect 
a lower maximum ratio of four, rather than eight, Hb bound to PEG if there is one 
hundred percent reactivity. This method utilizes thiol-maleimide click chemistry to 
produce a PEG Hb polymer distinguishable from all other PEG Hb products reported 
thus far. As a large PEG backbone is covered by multiple proteins, the reverse of 
traditional PEGylation schemes, we have called this method inside-out PEGylation. 
Here we show that this form of PEGylation can create a PEG XL-Hb polymer via site 
specific chemistry that has the potential to be a viable HBOC for highly hypoxic 
tissues. 
Materials 
 Untreated bovine blood was obtained from Animal Technologies (Tyler, TX). 
Eight Arm Maleimide-PEG (Mal-PEG) was purchased from Creative PEGWorks 
(Winston Salem, NC). Sephadex chromatography media were purchased from GE 
Healthcare Biosciences (Pittsburg, PA). Micro separatory centrifuge filters (300 
kDa) were purchased from Sartorius Stedim (Bohemia, NY). Hemox Antifoam and 
the HEMOX oxygen analyzer were purchased from TCS Scientific (New Hope, PA). 
DBSF was made by the method of Zaugg et al (Zaugg, King, Klotz 1975). All other 
chemicals and gel filtration markers kit for protein molecular weights 29 kDa - 700 
kDa were purchased from Sigma-Aldrich Co. (St. Louis, MO). 
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Methods 
Bis(3,5-dibromosalicyl) Fumarate (DBSF) Synthesis and Conformation 
Bis(3,5-dibromosalicyl) fumarate (DBSF) was prepared by a procedure 
similar to that for the succinate diester done by Walder et al. (Walder et al. 1979) 
1.35 mL (0.0125 moles) of fumaryl chloride was mixed with 100 mL of benzene 
(toluene can be substituted for benzene). Following that, 7.55 grams (0.0255 moles) 
of 3,5-dibromosalicylic acid and 6.38 mL (0.05 moles or 6.06 g) of N,N-
dimethylaniline were added to the previous mixture. The slurry was allowed to mix 
at room temperature for three hours. After which, thirty mL of ice-cold deionized 
water were added and the mixture was acidified with a few drops of 12 M HCl and 
allowed to stir for another 20 minutes.  The liquid was decanted off, and the solid 
was washed three times with benzene/toluene via vacuum filtration. The sample 
was then allowed to dry and it was scraped into a beaker in which just enough 
acetone was added to dissolve the DBSF (the solution became clear not cloudy) and 
an equal amount of water was added. If the DBSF came out of solution slightly, more 
acetone was added to make the mixture clear. The sample was then put through a 
vacuum filtration system to remove any solid particles that did not dissolve in the 
acetone/water and the liquid was collected. Following this, 6 M HCl was added to 
the mixture until the DBSF was seen to precipitate out of solution, and turned 
cloudy again. If the pH was lowered, and the DBSF did not come out of solution, 
water was added to help the DBSF precipitate out. Figure five shows the scheme by 
which DBSF was synthesized. The mixture was once again run though the filtration 
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system, and the solid DBSF was collected. The product, C18H8O8Br4•C2H6O, had a 
melting point of 223-225oC. 
Around seven mg of the produced DBSF, Sigma Aldrich’s DBSF, and LKT 
Laboratories DBSF were taken and separately suspended in deuterated acetone 
(Acetone-d6). NMR spectra were taken of each sample on a Gemini-300. The solvent 
was not ideal to produce a reliable NMR spectrum, so the procedure was repeated 
the same as before but deuterated acetone was substituted for deuterated DMSO 
(DMSO-d6).  
 
             
          +               2 
 
 
                                                         Benzene (100 mL)                        
                                                                                  N, N-dimethylanaline (0.05 mols) 
 
 
 
 
 
Figure 5. Synthesis of DBSF. 
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Crosslinked Hemoglobin Synthesis 
Methods described by Hanash and Shapiro (Hanash and Shapiro 1981) and 
Dozy et al. (Dozy, Kleihauer, Huisman 1968) were modified for the purification of 
Hb from bovine blood. After ammonium sulfate fractionation and dialysis, the 
impure Hb solution was added to Sephadex A-50 gel in 50 mM Tris, 1 mM NaCN, pH 
8.5 buffer in centrifuge tubes.  Unbound proteins were separated by centrifugation 
and then the bound Hb was released from the gel upon the addition of Tris buffer at 
pH 7.2. The procedure for crosslinking oxy-hemoglobin was carried out as outlined 
by Walder et al. (Walder et al. 1979).  DBSF was reacted with oxy-hemoglobin at a 
molar ratio of 1 Hb: 1.2 DBSF at room temperature for four hours before dialysis in 
50 mM Tris, 1 mM NaCN pH 8.5 buffer. Separation of unmodified Hb from βXL-Hb 
was accomplished by a pH gradient of 8.5 to 6.8 on a Kontes Chromaflex column 
using Sephadex A-50 gel in 50 mM Tris, 1 mM NaCN buffer. SDS-PAGE procedures, 
outlined by Schmidt et al. (Schmidt and Brosious 1979), showed equal intensity 
bands at 14.4 kDa and 30 kDa, verifying crosslinking. 
Reduction of Methemoglobin to Oxyhemoglobin 
 The procedure used was a revised version of the Dixon and McIntosh method 
(Dixon and McIntosh 1967). A 25 cm x 1 cm Kontes column was loaded with 
Sephadex G-25 gel in 5 mM phosphate buffered saline solution (PBS) pH 7.0, 1 mM 
EDTA buffer. Following equilibration, 0.5 mL of a 0.1 g/mL solution of sodium 
dithionite was added to the column followed by addition of 0.3 mL of the PBS buffer. 
A 5 mL sample was then passed through the gel and reduced by the dithionite.  
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PEGylation of Crosslinked Hemoglobin 
XL-Hb was dialyzed in 50 mM MOPS, 10 mM EDTA, pH 7.4 buffer.  The 
sample was then passed through a 0.2 micron filter to remove any particulates. XL-
Hb was then reacted with a 40 kDa, 8-Arm Mal-PEG at a molar ratio 80 XL-Hb: 1 
Mal-PEG at room temperature for one week.  Unreacted Hb was removed using a 
300 kDa micro separatory centrifuge filter spun at 2950 g. The retained complex 
was collected for further purification.   
Purification of PEGylated Crosslinked Hemoglobin via Size Exclusion Chromatography 
A pre-packed Sephacryl S-300 column was equilibrated with 50 mM MOPS, 
0.15 M NaCl, pH 7.4 buffer. Concentrated samples retained by the 300 kDa filter 
were then applied, and the large molecular weight PEG XL-Hb fractions were 
collected and concentrated. The concentrated samples were then ran on a pre-
packed Sephacryl S-500 column that was previously equilibrated with 50 mM 
MOPS, .15 M NaCl, pH 7.4 buffer. Known protein standards were ran to determine a 
standard curve. 
SDS-PAGE of PEGylated Hemoglobin 
Confirmation of large molecular weight species produced by PEGylation of 
XL-Hb was obtained using a PhastGel SDS-PAGE system (Schmidt and Brosious 
1979).  
Determination of Molecular Weight via Analytical Ultracentrifugation (AUC) 
AUC was carried out in a Beckman Coulter ProteomeLab XL-A analytical 
ultracentrifuge using standard 2 sector cells with quartz windows in 4- or 8-hole 
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rotors. All sedimentation velocity experiments were at 50,000 rpm with a preset 
scan number of 100 per cell. The reference sector was filled with 450 µL of buffer 
(50 mM MOPS, 10 mM EDTA, pH 7.4) and the sample sector was filled with 430 µL 
of sample with an absorbance at 412 nm (1 cm path length) between 0.75 and 1.1. 
Buffer density (1.00718 g/mL) was measured at 20.0 C in a Mettler/Paar 
Calculating Density Meter DMA 55A and the buffer viscosity (0.010543 Poise) was 
measured in an Anton Parr AMVn Automated Microviscometer. A partial specific 
volume of 0.746 mL/g for bovine hemoglobin was used in calculating molecular 
weight (DeMoll et al. 2007). Data were analyzed using the program Sedfit 
(www.sedfit.com). Molecular weights and sedimentation coefficients were 
determined using the continuous c(s) mode in the sedfit program. Native tetrameric 
hemoglobin yielded an s20,w value of 4.25S which agrees with the accepted value 
(Field and O'Brien 1955). The c(s) plots were deconvoluted using nonlinear least-
squares fitting algorithms available in the Origin (v. 9.0) software package 
(OriginLab Corporation, Northapmton, MA).  Data were fit to multiple Gaussian 
components, increasing the number of components until residual plots (data-fit) 
were random and the chi square value for the fit was minimal.  Six components were 
needed to adequately describe the c(s) distribution. 
Secondary Structure Characterization of PEG XL-Hb via Circular Dichroism 
CD spectra were obtained on an OLIS DSM 20 CD Spectrophotometer. Water 
was used to collect baseline data and as the dilution solvent for the Hb samples. The 
final Hb concentrations in the cuvette for the three samples were 0.01420 mg/mL 
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PEG XL-Hb, 0.02301 mg/mL Hb, and 0.02238 mg/mL XL-Hb. For each sample a 
wavelength range from 190-260 nm was scanned. The spectra were smoothed using 
Solvitsky Golay 7 point method (Whitmore and Wallace 2004; Whitmore and 
Wallace 2008). 
Thermal Denaturation Procedure 
Experiments followed the procedure according to Olsen (Olsen 1994). 
Experiments were conducted in 10 mM MOPS, 0.9 M guanidine HCl pH 7.0. Samples 
were prepared so that the absorbance at 409 nm was between 1 and 1.2. Samples 
were monitored every minute on an Agilent 8453 spectrophotometer. A 
temperature increase of 0.3C/ min was controlled by Neslab Endocal, Temperature 
Programmer ETP-3, and Digital Controller/Readout DCR-4. Absorbance versus 
temperature was plotted and the fraction denatured was determined by the 
equation FD = (A-AN) / (AD-AN) where A is experimental absorbance, AN is 
absorbance of native protein, and AD is absorbance of denatured protein. AN  and AD 
were determined by fitting a linear line to the portion of the absorbance versus 
temperature plot that corresponded to the effect of temperature on the native or 
denatured spectrum respectively. The curve of FD versus temperature was 
smoothed in Microsoft Excel with an exponential smoothing function. 
Autoxidation Experiments 
 Autoxidation of native, crosslinked, and PEG crosslinked hemoglobin was 
carried out according to Yang and Olsen (Yang and Olsen 1989). Hemoglobin 
samples were fully reduced and dialyzed in 10 mM MOPS, pH 7.0. Sodium cyanide 
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was added to each sample and allowed to equilibrate at room temperature for five 
minutes prior to data collection. The experiments were conducted at 37C and 
allowed to equilibrate before spectra were recorded from 500-700 nm on an Agilent 
8453 spectrophotometer.  
Oxygen Binding Studies For Determination of P50 and Hill Coefficients 
 The samples, fully reduced with dithionite, were added to 4.0 mL of 10 mM 
MOPS, pH 7.4 and 10 L of Hemox Antifoam. Oxygen binding was determined using 
a HEMOX Analyzer for native bovine Hb, native Hb with inositol hexaphosphate 
(IHP), XL-Hb, XL-Hb with IHP, and PEG XL-Hb. Hill coefficients (n) and oxygen 
affinity (P50) were obtained from Hill plots. 
Results 
Bis(3,5-dibromosalicyl) Fumarate (DBSF) Synthesis and Conformation 
As seen in Figures 6-8 (self-synthesized, Sigma, and LKT Laboratories DBSF) 
via the NMR spectra that there are three noteworthy peaks between 7.2 ppm and 
8.6 ppm. The integration of these peaks in each of the H-NMR were calculated to be 
δ 8.35(2Hd, J=2.1 Hz), 8.10(2Hd, J=2.1 Hz), 7.35(2Hs), δ 8.35(2Hd, J=2.4 Hz), 
8.10(2Hd, J=2.4 Hz), 7.35(2Hs), and δ 8.35(2Hd, J=2.7 Hz), 8.10(2Hd, J=2.4 Hz), 
7.35(2Hs) for self-synthesized, Sigma, and LKT Laboratories DBSF respectively. The 
two peaks between 8.0-8.4 ppm corresponds to the aromatic hydrogens, while peak 
at 7.35 corresponds to the aliphatic hydrogens. This verified a successful DBSF 
synthesis in relation to Sigma and LKT Laboratories purchased DBSF by the nearly 
identical H-NMR spectra. 
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Figure 6. Self-synthesized DBSF H-NMR spectrum in DMSO-d6 solvent with an ex-
panded spectrum above showcasing the range 7.2 ppm to 8.6 ppm. The peaks of 
interest and their integration can be seen at δ 8.35(2Hd, J=2.1 Hz), 8.10(2Hd, J=2.1 
Hz), 7.35(2Hs). 
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Figure 7. Sigma purchased DBSF H-NMR spectrum in DMSO-d6 solvent with an ex-
panded spectrum above showcasing the range 7.2 ppm to 8.6 ppm. The peaks of 
interest and their integration can be seen at δ 8.35(2Hd, J=2.4 Hz), 8.10(2Hd, J=2.4 
Hz), 7.35(2Hs). 
 
 
 
 
 
 
37 
 
 
 
 
 
Figure 8. LKT Laboratories purchased DBSF H-NMR spectrum in DMSO-d6 solvent 
with an expanded spectrum above showcasing the range 7.2 ppm to 8.6 ppm. The 
peaks of interest and their integration can be seen at δ 8.35(2Hd, J=2.7 Hz), 
8.10(2Hd, J=2.4 Hz), 7.35(2Hs). 
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XL-Hb Reaction Verification 
Figure nine depicts the crosslinked Hb tetramer under oxy-conditions in 
which the fumarate from the DBSF molecule links the Lys821 and Lys822. This 
oxyhemoglobin crosslinking occurs on the -subunit end of the central cavity in the 
Hb tetramer. Because it stabilizes the R state of Hb, the XL-Hb already shows a 
higher affinity for oxygen than standard Hb within a RBC or even uncrosslinked Hb. 
Verification of this XL-Hb product was seen via SDS (Figure 10) with distinct bands 
around both 14.4 kDa and 30.0 kDa, ideally of equal intensity. Each Hb monomer is 
around 15 kDa, so the band at 14.4 kDa is representative of the alpha subunits 
disociation, where the band around 30.0 kDa indicates that the beta subunits were 
in fact linked together.  
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Figure 9. Model of oxy-XL Hb. DBSF crosslinks within the central cavity at the 2,3-
BPG binding site. 
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Figure 10. SDS confirmation of the crosslinked Hb Product. Lanes 1 and 4 are the 
markers while 2, 3, 5, and 6 are samples of XL Hb. The band at 14.4 kDa is a result 
from the alpha subunit separation from the Hb tetramer, while the band around 
30.0 kDa is a result of the XL beta subunits. 
 
XL-Hb Purification Verification 
The separation of uncrosslinked Hb, XL-Hb, overly crosslinked Hb and 
MetHb by Sephadex A-50 gel is possible due to the removal of two positive charged 
residues (Lys821 and Lys822) on the overall protein. This means that the less 
positive XL-Hb will bind to the gel more tightly then the more positive 
uncrosslinked Hb. As the pH of the buffer is lowered, the various Hb species will 
gain positive charges and will be released from the gel. The species of Hb elute from 
the column in the order: native Hb, Xl-Hb, overly Xl-Hb, and finally (with a drastic 
pH drop) MetHb. Overly XL-Hb will be more negative as other Lys groups (besides 
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the desired Lys821 and Lys822) have reacted with DBSF. Figure eleven shows the 
absorbance at 415 nm via UV-Vis in relation to the fraction number coming off the 
column. By looking at the data in Figure 11, it is evident that there were at least 
three major peaks as expected. The fractions were pooled together for each peak 
and SDS was run to determine which pools contained the purest samples of XL-Hb. 
Figure 12 shows two SDS gels side-by-side that represents the eight pools. Figure 
12, reading left to right, lanes 3, 5, 10, and 12 are markers while the left most lane 
(1) is the pool collected from the fractions that were last to come off the column and 
lane eleven is the pool collected from the beginning fractions. It can be seen reading 
left to right that the 30.0 kDa band becomes fainter until it disappears in the sample 
in lanes nine and eleven. This agrees with the fact that uncrosslinked Hb elutes off 
the column first, followed by XL-Hb as is seen by the darkening presence of the 30.0 
kDa band indicating Lys821 Lys822 crosslinking.  
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Figure 11. Graph of UV-Vis Spec Samples from Ion Exchange Column Fractions. The 
wavelength at 415 nm was used because at this wavelength the absorbance is 
specific for the heme group within the Hb. Wavelengths at 542 nm, and 578 nm are 
also for the heme groups but were not used to generate the chromatogram. It is 
apparent that there are 3 distinct peaks which correlate to un-crosslinked Hb, XL-
Hb, and finally overly XL-Hb. 
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Figure 12. SDS from Ion Exchange Column Pulls. Lanes 3, 5, 10, 12 are the marker 
while the other lanes are from the 8 pulls created from the fractions shown in figure 
11. Reading from right to left, the pulls correlate from early fractions that were 
collected to the last fractions collected. As seen in lanes 9 and 11 there is only a band 
present at 14.4 kDa correlating to complete Hb dissociation of the four monomers. 
Continuing reading right to left the band at 30.0 kDa becomes increasingly darker 
correlating to a higher production of XL-Hb. 
 
 
 
Crosslinked Hemoglobin (XL-Hb) Production and Confirmation of PEGylation at 
Cysteine 93 Residue 
Verification of XL-Hb product was obtained with SDS-PAGE (Figure 13) that 
showed distinct bands of equal intensity around 14.4 kDa and 30.0 kDa. An absence 
of the 30.0 kDa band with the concomitant presence of a new band at the origin of 
the gel (Figure 13, lane 3) was present in the PEGylated Hb sample. 
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Figure 13. SDS Verification of PEG XL-Hb. Lanes 2 and 4 are the marker proteins, 
while Lane 1 is XL-Hb and Lane 3 the PEG XL-Hb sample. 
 
Conformation of Large Molecular Weight Species and Purification of PEG XL-Hb from 
Unreacted XL-Hb 
Preliminary purification was accomplished by use of a 300 kDa filter, where 
XL-Hb passed through the filter while the PEG XL-Hb compound was retained. 
The PEGylated sample was further purified with an S-300 column (Figure 14) and 
the large molecular weight species were then applied to an S-500 column for 
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additional purification and characterization. It was evident from size exclusion 
chromatography (SEC) that PEG XL-Hb and unreacted XL-Hb Hb can be 
successfully separated with this two phase SEC protocol. On the S-500 column the 
characteristic elution peak around 250 mL was XL-Hb, while the elution peak 
around 220 mL was the large PEG XL-Hb sample (Figure 15).  
 
 
 
Figure 14. Normalized PEG XL-Hb SEC chromatogram from the S-300 column. 
Unreacted XL-Hb eluted around 80 mL while the larger PEG XL-Hb product eluted 
between 40 and 65 mL. All four samples were prepared in the same method on 
different days. 
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Figure 15. A normalized chromatogram from the S-500 column of a PEG XL-Hb 
(Red) sample post S-300 SEC and an un-PEGylated XL-Hb sample (Blue). Unreacted 
XL-Hb elutes around 250 mL while the larger PEG XL-Hb product elutes around 
220 mL. 
 
Size Determination of PEG XL-Hb Samples via Analytical Ultracentrifugation 
 Figure 16A shows the Analytical Ultracentrifugation (AUC) sedimentation 
velocity analysis of the PEG XL-Hb purified with a S-300 column and subsequently 
by S-500 column (see Figure 15). Sample heterogeneity was observed by monitoring 
the amount of product in relation to sedimentation coefficients. Native Hb has a s20,w 
of 4.25S (Field and O'Brien 1955) indicating that larger species are PEGylated 
samples. Most (60%) of the species lie in the sample range from 3 Hb : 1 PEG to 8 
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Hb : 1 PEG. The sample was heterogeneous in composition but there was a 
consistent pattern of heterogeneity between different samples. Figure 16B shows a 
deconvolution of a c(s) versus s20,w indicating the predominant HBOC species as 3 
Hb : 1 PEG. 
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Circular Dichroism Analysis of Secondary Structure in PEG XL-Hb 
Circular Dichroism (CD) was used to determine if crosslinking and 
PEGylation perturbed the secondary structure of Hb. Spectra of native Hb, XL-Hb, 
and PEG XL-Hb showed the characteristic signals for alpha helical structure at 195, 
208, and 222 nm (Figure 17). Hemoglobin is 75% alpha helical by nature. 
 
 
 
 
 
 
Figure 17. CD spectra of native Hb (green), XL-Hb (blue), and PEG XL-Hb (red). 
All three spectra show the characteristic signals for alpha helical structure at 195 
nm, 208 nm, and 222 nm. 
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Thermal Denaturation of Hb Samples 
 Thermal denaturation curves for native Hb, XL-Hb, and PEG XL-Hb (Figure 
18) showed that crosslinking and PEGylation increase the stability of the Hb 
tetramer compared to native Hb (Figure 18). The melting temperatures (Tm) for the 
samples can be seen in Table 4. A single factor ANOVA showed that the differences 
between all the Tm values are statistically significant. 
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Autoxidation of Hb Samples 
 Autoxidation experiments were conducted at 37C to see the effects of 
crosslinking and PEGylation on the autoxidation rates at physiological 
temperatures. Table 4 contains the relative rate constants (krel) of autoxidation. The 
relative rate constants were determined by dividing the slopes of methemoglobin 
production for XL-Hb and PEG XL-Hb by the slope of native Hb. It was determined 
that crosslinking increased Hb autoxidation rate by 1.59 times and PEGylation 
further increased the autoxidative rate to 3.43 times that of native Hb. Figure 19 
shows the spectral changes observed in the PEGylated Hb sample. There was a 
decrease in the oxyhemoglobin absorbance at 540 and 576 nm as the sample 
autoxidized.   
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Figure 19. Autoxidation and spectral changes in PEG XL-Hb sample. The spectra 
showed a decrease in absorbance at 576 and 540 nm and an increase of absorbance 
at 630 and 510 nm as the sample was allowed to oxidize. 
 
Oxygen Binding Determination of Hb Samples 
Figure 20 shows the experimental determined oxygen binding curves. Table 
4 shows the calculated P50 and Hill coefficients (n) determined for native Hb, XL-
Hb, and PEG XL-Hb. The XL-Hb species had a higher oxygen affinity than native, 
stroma-free hemoglobin as expected (Walder et al. 1979). The addition of Inositol 
Hexaphosphate (IHP) to native Hb shifted the oxygen binding curve to the right but 
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addition of IHP to XL-Hb and PEG XL-Hb did not show this shift. The PEG XL-Hb 
sample had a similar oxygen affinity to XL-Hb. The Hill coefficients showed that the 
cooperativity of Hb decreased (from 2.91 to 1.72) once Hb was crosslinked 
(stabilizing the R state) and decreased slightly more following PEGylation (1.72 to 
1.43). 
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Table 4. Experimentally determined Tm (C) from fraction denatured curves, relative 
rates of autoxidation at 37C, and P50 (torr) and Hill Coefficients determined at 37C 
for native bovine Hb, XL-Hb, and PEG XL-Hb. 
 
Sample Tm (°C)* krel  P50 (torr) Hill Coefficient (n) 
Native Hb 41.3 ± .9 1 11.25 ± .17 2.91 ± .06 
XL-Hb 54.1 ± .5 1.59 ± .15 9.16 ± .84 1.72 ± .06 
PEG  XL-Hb 48.9 ± 1.5 3.43 ± .53 9.67 ± .39 1.43 ± .06 
*ANOVA F=80.0, Fcrit=3.5 
 
 
Discussion 
 
An inside-out PEG XL-Hb polymer was successfully produced by reacting 
the Cys 93 residue of the Hb tetramer with an 8-armed PEG.  The SDS-PAGE of XL-
Hb (Fig. 13) showed a band at 30.0 kDa indicative of the β subunits covalently linked 
together by bis-(3,5-dibromosalicyl)fumarate  (DBSF) under oxy-conditions while 
the band at 14.4 kDa was due to the α monomers. The PEGylated product showed 
the absence of the 30.0 kDa band, specific for the XL subunits, and the presence of a 
new band at the origin suggesting successful PEGylation. The conserved presence of 
the  subunit band at 14.4 kDa in the PEG XL-Hb sample indicates a lack of 
PEGylation on these subunits. The Cys 93 residue is the only cysteine available in 
bovine Hb for thiol-maleimide click chemistry. Unlike human Hb, bovine Hb has only 
one Cys residue on each  chain for thiol-maleimide specific click chemistry; there 
are no Cys residues on the  chains of bovine Hb.  
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It has been found that increasing the Hb polymer size is one way to 
counteract vasoactivity (Harrington and Wollocko 2011; Martini et al. 2006; 
Matheson et al. 2002; Palmer 2006; Palmer and Intaglietta 2014). A larger polymer 
will move in the center of the blood flow preventing NO scavenging from endothelial 
tissue (Palmer 2006; Palmer and Intaglietta 2014). Inside-out PEGylation was used 
to produce a Hb nanoparticle. Polymer size determination and characterization 
were accomplished by gel filtration and AUC. It was found that the samples were 
heterogeneous, but reproducible in their pattern of heterogeneity (Figure 16A). The 
polymeric species could not be resolved with S-500 size exclusion chromatography 
(Figure 15). The calculated apparent molecular weight of the sample was around 
500 kDa based on the standard curve from protein standards. However, the elution 
volume was nearly identical to that of the apoferritin standard (443 kDa). While 
these results would indicate a complex of 7 Hb : 1 PEG, the apparent molecular 
weight determined by this technique does not represent the actual polymer mass 
due to the large hydrodynamic volume of the PEG. Previous PEGylated HBOCs have 
been shown to have a large increase in their volume and hydrodynamic radius. The 
volume can increase over ten times what it was originally while the hydrodynamic 
radius can more than double when compared to that of native hemoglobin (Hu et al. 
2007; Li et al. 2008; Meng et al. 2014; Wang et al. 2014). In addition, appropriate 
standards for the PEGylated samples are not available. As a result, PEGylation would 
be expected to yield a larger apparent molecular weight by SEC when compared to 
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traditional protein standards as seen in the product. It is speculated, however, that 
the data indicates how the polymer size would appear in vivo.  
Although Hb is in high molar excess for the reaction, an 8 Hb : 1 PEG is not 
the major polymer species, as shown by the AUC results (Figure 16). After the 
reaction of a tetramer to one arm of the PEG the probability of an unreacted arm 
reacting with the other exposed thiol of the same Hb is greatly increased. As seen in 
figure 16A, 60% of the polymer species possess three to eight Hb tetramers 
conjugated onto one Mal-PEG backbone. The deconvolution data (Fig. 16B) indicates 
that there are four predominant PEG XL-Hb species being produced. Three of the 
four species have three to six Hb tetramers conjugated to one Mal-PEG. The peak 
near 2.5S is unconjugated hemoglobin. The data indicates the major product is 3 
Hb : 1 PEG complex, shown diagrammatically in Figure 21. The broadening of the 
major peak in Figure 16B shows the difficulty in separating the 3 Hb and 4 Hb 
species. Maleimide-derived click chemistry shows a high specificity for thiol groups 
but is not restricted to these reactions. Maleimide reactions with Lys residues are 
much less favorable at pH 7.4 than to Cys residues, yet plausible (Dondoni 2008; 
Hoyle and Bowman 2010; Khan 1985).    
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Figure 21. Schematic representation of Inside-out PEGylated crosslinked 
hemoglobin. While possible to conjugate eight Hb tetramers to one PEG polymer, it 
is more probable two arms will bind to a single tetramer. The major species 
produced is depicted above (3 Hb : 1 PEG). 
60 
 
The large size of a 3 Hb: 1 PEG species will likely prevent the HBOC from 
coming into close proximity with the arterial lining, thus preventing NO scavenging 
in vivo (Palmer 2006; Palmer and Intaglietta 2014). As observed for PEGylated 
HBOCs of comparable size, the size of inside-out PEGylated Hb should be sufficient 
to eliminate vasoconstrictive side effects (Bjorkholm et al. 2005; Li et al. 2007; 
Vandegriff et al. 2003). The increased volume of the PEG XL-Hb complex will also 
hinder filtration of the polymer by the kidneys, increasing circulation time in vivo 
(Conover et al. 1997; Vandegriff et al. 2003). Crosslinking of the tetramer prevents 
its dissociation, reducing concerns of nephrotoxicity. These modifications increase 
the stability of the Hb tetramer as seen in the fraction denatured results when 
compared to native Hb (Table 4). Thermal denaturation experiments (Figure 18) 
showed that crosslinking greatly increases the stability of the tetramer compared to 
that of native Hb (Native Hb = 41.3C, XL-Hb = 54.1C) (White and Olsen 1987). 
PEGylation lowers the stability of the tetramer (48.9C) compared to the XL-Hb 
species but the PEGylate species is still more stable than native Hb. This indicates 
that crosslinking dictates the tetramer stability more than inside-out PEGylation.  
While crosslinking and inside-out PEGylation increase the stability of the 
tetramer, it also increases the autoxidation rate of Hb. It has been previously shown 
that crosslinking under oxy-conditions with DBSF increases the rate of oxidation 
(Yang and Olsen 1989). The data presented here agrees with previously reported 
krel values and spectral changes affiliated with autoxidation of the heme (see Figure 
19 and Table 4). Upon PEGylation, the rate of oxidation increases significantly to 
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3.43 times that of native Hb. Previous work has shown that PEGylation of Hb 
increases the rate of autoxidation. Acharya and coworkers showed that PEGylated 
Hbs exhibit a 2-3 fold increase in oxidation rates (regardless of the methodology 
used for PEGylation) when compared to native Hb (Hu et al. 2008). It is also known 
that conjugation of PEG onto Cys 93 shows a faster rate of oxidation when 
compared to PEGylated Hb species that are modified on Lys residues (Hu et al. 
2008; Wang et al. 2014). Cys 93 is adjacent to the proximal His that coordinates 
with the iron in the heme. PEGylation on this residue perturbs the heme 
environment allowing a larger number of water molecules to enter and facilitate 
oxidation. In addition, PEGs also have the unique property to sequester 
approximately 2-3 water molecules per repeating unit (Hu et al. 2005), increasing 
the odds for water-mediated oxidation. However, it has been speculated that the 
rate of autoxidation will be less in vivo due to antioxidant and reducing agents 
present within plasma (Hu et al. 2008; Snyder et al. 1987; Yang and Olsen 1989). 
Addition of IHP with no observable shift in oxygen affinity for XL-Hb 
verified the success of the oxy-crosslinking procedure between the 82 Lys residues 
that blocks the allosteric binding site (Walder, Walder, Arnone 1980). The Cys 93 
residues are exposed only within the R state tetramer, and conjugation to this site 
produces a higher oxygen affinity Hb (Abraham, Phillips, Kennedy 1983). Previous 
studies also demonstrated that an increased oxygen affinity was a byproduct of 
PEGylation, independent of the conjugation site (Li et al. 2009). The data presented 
here show that the conjugation of PEG to Cys 93 does not further increase the 
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oxygen affinity if the Hb is previously crosslinked in a high oxygen affinity state, 
unlike other PEGylated HBOCs (Table 1). XL-Hb stabilizes the R state conformation 
of the tetramer, increasing oxygen affinity in comparison to stroma-free Hb. 
Negligible changes were found between P50 values for XL-Hb (9.16 torr) and PEG 
XL-Hb (9.67 torr). Other PEG-based HBOCs have exhibited large increases in 
oxygen affinity post crosslinking and PEGylation (P50 from 3-6 Torr) (Hu et al. 2007; 
Li et al. 2008; Li et al. 2009; Lui, Dong, Kluger 2008; Lui et al. 2012).  Crosslinking 
and inside-out PEGylation dramatically decrease the cooperativity of the Hb 
tetramer (Table 4). There were negligible differences between the three samples CD 
spectra indicating that crosslinking and PEGylating hemoglobin do not significantly 
change the secondary structure of the protein (Figure 17) (Sreerama, Venyaminov, 
Woody 2000; Whitmore and Wallace 2004; Whitmore and Wallace 2008). Thus, the 
loss of cooperativity is not a result of secondary structure conformational changes, 
but rather from chemical modifications. Crosslinking of the tetramer restricts the 
movement needed for cooperativity, while PEGylation may further restrict 
quaternary structural change. The heightened oxygen affinity ensures that the 
polymers will be fully oxygenated leaving the lungs and will only deliver it to the 
most oxygen deficient tissues. This in turn will help prevent tissue necrosis in 
patients who have lost severe amounts of blood. 
The inside-out PEG βXLHb presented here represents both a poly Hb and a 
dendrimeric structure.  Several other poly or dendrimeric hemoglobins have been 
produced by both genetic and chemical means. Genetically, placements of Cys 
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mutants at specific positions have led to the production of polymeric dimers, 
trimers, and octamers of Hb tetramers (Bobofchak et al. 2003; Fablet et al. 2003; 
Faggiano et al. 2011; Fronticelli et al. 2001; Vasseur-Godbillon et al. 2006).  The 
largest of these was ~500KDa in mass and had a diminished pressor compared to 
cross-linked tetrameric Hb, presumably due to a decreased extravasation 
(Bobofchak et al. 2003).  Thus, the same result is expected for the PEGβHb reported 
here.  Kluger and Zhang (Kluger and Zhang 2003) have reported the synthesis of a 
Hb dendrimer made by attaching β cross-linked Hb to generation 4.0 
polyamidoamine dendrimer (PAMAM).  As expected the product had very high 
oxygen affinity.  Kluger and co-workers (Singh et al. 2015b) also produced bis-
tetrameric Hb using double cross-linking and click chemistry.  The advantage of 
these approaches is the specificity of the connections between the Hb tetramers 
making the polyHb, but the disadvantage is the amount of genetic manipulation or 
chemical synthesis needed to produce such products.  Inside-out PEGylation offers 
the possibility of making similar sized polyHbs with commercially available 
reagents.  In addition, the methods presented here should be easily applicable to 
many other proteins. 
Conclusions 
We have successful produced an inside-out PEGylated XL-Hb complex. 
Inside-out PEGylation has been shown to maintain secondary structure, increase 
protein stability, without altering the P50 value compared to the native protein. 
Unlike previous PEGylated HBOCs, inside-out PEGylation does not dictate protein 
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function, specifically the oxygen affinity. The functional properties of the polymer 
are controlled by the method under which Hb was crosslinked. This form of protein 
modification has applications in many areas of biochemistry beyond HBOC 
development, such as PEGylation of drug delivery agents and applications with 
other protein therapeutics. In the past there have been a few dendrimeric Hb 
particles produced (Fablet et al. 2003; Fronticelli et al. 2001; Kluger and Zhang 
2003). However, none of these have utilized multi-arm PEGs in their production. 
Until now multi-arm PEGs have primarily been utilized in the creation of hydrogels 
and biofilms (Guebeli et al. 2012; Meyerbroeker, Kriesche, Zharnikov 2013). The 
results reported here introduce applications of multi-arm inside-out PEGylation that 
can be used in protein chemistry and enzymology. Applications of inside-out 
PEGylation could be expanded to the production of multi-enzyme complexes. Inside-
out PEGylation may be efficacious in biomacromolecular production and in 
bioconjugate chemistry. 
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CHAPTER IV 
“INSIDE-OUT” PEGYLATION OF BOVINE -CROSSLINKED HB VIA STRAIN 
PROMOTED AZIDE-ALKYNE CYCLOADDITION 
Chapter Introduction 
A viable alternative to current blood transfusions has been actively pursued 
for several decades with varying degrees of success. A limited supply of blood, 
dependent on human donors, has necessitated the creation of a hemoglobin-based 
oxygen carrier (HBOC) derived from non-human sources. Such a product would be 
responsible for carrying oxygen to hypoxic tissues and might be useful as a response 
to hemorrhagic trauma. However, a HBOC has a utility that exceeds applications in 
hemorrhagic shock.  It may also be used to treat carbon monoxide poisoning, acute 
anemia, organ ischemia, and cardioplegia—all of which induce oxygen deprivation 
(Jahr, Akha, Holtby 2012). The value of such a product would be augmented if it 
could be minimally refrigerated, non-immunogenic, universal for all blood types, 
and available at a minimal cost whilst possessing a long shelf life (Estep et al. 2008; 
Ness and Cushing 2007; Reid 2003; Sakai et al. 2000). All hemoglobin-based oxygen 
carriers must begin with source of hemoglobin. However, application of stroma-free 
unmodified hemoglobin (Hb) to a living system results in complications. The Hb 
tetramer dissociates into two  dimers whose small size enables 
66 
 
 
them to pass into the kidneys where nephrotoxicity is observed. The short 
circulation time associated with an unmodified Hb tetramer does not mitigate the 
impact of another harmful effect—vasoconstriction induced by the scavenging of 
nitric oxide, a natural vasodilator found in the endothelial walls (Doherty et al. 
1998; Muldoon et al. 1996; Reid 2003).  The avoidance of vasoconstriction and 
tetramer dissociation while maintaining the ability to deliver oxygen efficiently has 
become the basis of all HBOC development.  
Crosslinking of extracted hemoglobin via the alpha subunits is one approach 
at preventing tetramer dissociation in vivo. This may be accomplished by the use of 
a crosslinking reagent, such as bis-(3,5-dibromosalicyl)fumarate (DBSF), under 
deoxy- conditions (Tye et al. 1983; Zaugg, King, Klotz 1975). Crosslinking of the Hb 
tetramer under oxy- conditions using this same reagent likewise prevents 
dissociation of the tetramer. However, these two modifications have opposite effects 
on the affinity with which the HBOC binds oxygen (White and Olsen 1987; Yang and 
Olsen 1991). HBOC polymer production methodologies have ranged from 
dentrimeric Hb, liposomal encapsulated Hb, bis-tetrameric Hb, and PEGylated Hb 
particle creation (Agashe and Awasthi 2009; Bradley et al. 2002; Fablet et al. 2003; 
Fronticelli et al. 2001; Kluger and Zhang 2003; Lui et al. 2012; Xiong et al. 2012). 
Production of a HBOC with a large molecular weight—by polymerization of Hb or 
conjugation of Hb to a polyethylene glycol (PEG) backbone—has been shown to 
attenuate vasoconstriction as seen with Hemospan produced by Winslow and 
colleagues (Bjorkholm et al. 2005; Vandegriff et al. 2003; Vandegriff and Winslow 
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2009). It has been found that a large polymer that cannot get close enough to the 
endothelial lining, thus preventing harmful NO scavenging (Martini et al. 2006; 
Palmer 2006; Palmer and Intaglietta 2014). Furthermore, polymers of large 
molecular weight, such as the Oxy Vita product developed by Bucci and colleagues 
(Matheson et al. 2002), have been shown non-vasoactive in vivo (Harrington and 
Wollocko 2011; Matheson et al. 2002). One method to generate a polymer with a 
large molecular volume is through PEGylation. PEG has been shown to sequester 
two to three water molecules per repeating unit, which can dramatically increase 
the hydrodynamic volume and polymer radius (Alayash 2004; Hu et al. 2005). 
General PEGylation of proteins has also increased the therapeutic value of the 
product by masking the protein from the immune system and preventing filtration 
through the kidneys (Bailon and Berthold 1998; Harris and Chess 2003; Roberts, 
Bentley, Harris 2002). Varying the size of the PEG chains, the number of chains 
conjugated to a protein, and the sites and methods of conjugation of PEG to Hb 
modulate the effects of PEGylation of a protein to different degrees (Hu et al. 2007; 
Li et al. 2008; Li et al. 2009). For example, conjugation of six PEG chains to a single 
Hb tetramer increases the oxygen affinity (Li et al. 2007). It has also been 
hypothesized that conjugation of Hb to a PEG mass greater than 50 kDa may 
counteract the vasoactivity of stroma free Hb in vivo (Rohlfs et al. 1998). 
This paper offers a modification of the unique scheme of “inside-out” 
PEGylation presented previously in Chapter 3 of this dissertation. The basic 
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stratagem of conjugating several bovine cross-linked Hb tetramers to a single eight-
arm 40 kDa PEG backbone remains unchanged. However, the PEG is conjugated to 
the Lysine residues of both the alpha and beta subunits of the tetramer. Such a 
conjugation necessitates two steps. Firstly, the Lysine -amino groups must be 
activated by reaction with dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-
NHS) via an NHS-ester mediated amidation. The alkyne of the subsequent product is 
then reacted with the azide group conjugated to one arm of the PEG backbone (N3-
PEG). In the past, copper (Cu+) mediated azide-alkyne cycloaddition (CuAAC) has 
been previously utilized to produce a bis-tetrameric hemoglobin oxygen carrier 
(Foot, Lui, Kluger 2009; Singh et al. 2015a; Wang and Kluger 2014; Yang and Kluger 
2010). These previous CuAAC have been efficacious in Hb polymer creation. 
However, the reaction presented here is not done via traditional copper mediated 
azide-alkyne click chemistry but rather by strain promotion found within the alkyne 
(Campbell-Verduyn et al. 2011; Gold et al. 2012). This removes any possible 
contamination of the final product by copper, which may have adverse medical 
effects (Campbell-Verduyn et al. 2011; Gold et al. 2012). Figure 22A shows the 
activation of a Lys on Hb, while Figure 22B shows the strain promoted azide-alkyne 
cycloaddition to achieve inside-out PEGylation. We believe this product will be a 
successful HBOC candidate to deliver oxygen nondiscriminatory to tissue rather 
than just to hypoxic tissue. 
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Materials 
Untreated bovine blood was obtained from Animal Technologies (Tyler, TX). 
Eight arm N3-PEG was purchased from Creative PEGWorks (Winston Salem, NC). 
Sephadex chromatography media were purchased from GE Healthcare Biosciences 
(Pittsburg, PA). Micro separatory centrifuge filters (300 kDa) were purchased from 
Sartorius Stedim (Bohemia, NY). Hemox Antifoam and the HEMOX oxygen analyzer 
were purchased from TCS Scientific (New Hope, PA). DBSF was made by the method 
of Zaugg et al (Zaugg, King, Klotz 1975). DIBO-NHS, all other chemicals, and gel 
filtration markers kit for protein molecular weights 29 kDa - 700 kDa were 
purchased from Sigma-Alrdrich Co. (St. Louis, MO). 
Methods 
Crosslinked Hemoglobin Synthesis 
Methods described by Hanash and Shapiro (Hanash and Shapiro 1981) and 
Dozy et al. (Dozy, Kleihauer, Huisman 1968) were modified for the purification of 
Hb from bovine blood. Sephadex A-50 gel in 50 mM Tris, 1 mM NaCN, pH 8.5 buffer 
was added to centrifuge tubes.  Hb was mixed thoroughly with the gel and 
centrifuged. The process was repeated three to five times until the supernatant 
coming off the gel was still red from Hb. The supernatants were then pooled and 
stored in the refrigerator until crosslinking. This method allows for rapid 
purification of large quantities of bovine Hb. 
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The procedure for crosslinking deoxy-hemoglobin was carried out according 
to Walder et al. (Walder et al. 1979).  Bis-(3,5-dibromosalicyl)fumarate (DBSF) was 
reacted with deoxy-hemoglobin  at a mole ratio of 1 Hb: 1.2 DBSF for four hours 
under wet nitrogen. The solution was then dialyzed in a 50 mM Tris, 1 mM NaCN, pH 
8.5. 
Sephadex A-50 was swelled in 50 mM Tris, 1 mM NaCN, pH 8.5 buffer and 
poured onto a Kontes Chromaflex column using a decreasing pH gradient.  The SDS-
PAGE protocol was followed according to Schmidt et al. (Schmidt and Brosious 
1979) and showed equal intensity bands at 14.4 kDa and 30 kDa. 
Reduction of Methemoglobin to Oxyhemoglobin 
 The procedure used was a modified version of Dixon and McIntosh’s method 
(Dixon and McIntosh 1967). A Kontes column, 25 cm x 1.0 cm, was loaded with G-25 
gel purchased from GE. The column was then equilibrated with 5 mM Phosphate 
Buffered Saline Solution (PBS), pH 7.0, 1 mM EDTA buffer. Following equilibration, 
0.2 g of sodium dithionite was added to 2.0 mL of the same buffer, and 0.4-0.6 mL of 
this solution was then added to the column followed by addition of 0.2-0.4 mL of the 
aforementioned buffer. A 5 mL sample of Hb was then added to the column and 
allowed to pass through the gel.  
Activation and PEGylation of Alpha Crosslinked Hemoglobin 
XL-Hb was dialyzed in 50 mM MOPS, pH 7.2 buffer.  The sample was then 
passed through a 0.2 micron filter to remove any debris or bacteria.  The 
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concentration of αXL-Hb was determined spectrophotometricaly to activate with 
Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-NHS) at a mole ratio of 1 
Hb : 1 DIBO-NHS or 1 Hb : 2 DIBO-NHS. The DIBO-NHS was first suspended in dried 
DMSO equal to 1% of the total reaction volume before being added to the αXL-Hb. 
The reaction was allowed to proceed for two hours at room temperature. Post 
activation, the sample was spun in a 30 kDa centrifugal separatory filter (Sartorius 
Stedim) at 4000 g and washed with 50 mM MOPS, pH 7.2 to remove any unreacted 
DIBO-NHS. The sample was then reacted with the 40 kDa eight arm azide-PEG at a 
16 Hb : 1 N3-PEG mole ratio. The reaction continued for one week either at room 
temperature or in a refrigerator. Following PEGylation, the PEG XL-Hb solution 
was placed in a 300 kDa micro separatory centrifuge filter and spun at 2950 g. 
Purification and Verification of PEGylation Alpha Crosslinked Hemoglobin 
Concentrated samples, post centrifugation, were run on a pre-packed 
Sephacryl S-300 column equilibrated with 50 mM MOPS, pH 7.2 buffer. The large 
molecular weight PEGylated XL-Hb fractions were collected and concentrated on a 
pre-packed Sephacryl S-500 (GE) for further purification and size determination. A 
standard curve was produced for the S-500 column using large molecular weight 
markers. 
SDS-PAGE Experiments with PEGylated Hemoglobin 
A 10 L aliquot of PEG αXL-Hb was added to 10 L of denaturing solution 
containing bromophenol blue in an Eppendorf tube. The same volume ratio was 
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used to make up αXL-Hb sample and protein marker. The samples were then placed 
in a boiling water bath for ten minutes to allow full denaturation. The samples were 
loaded on a 12.5% SDS homogenous gel. Following the run, the gel(s) was then 
placed in an auto-developer that stained, de-stained, and preserved the SDS gel 
(Schmidt and Brosious 1979).  
Determination of Molecular Weight via Analytical Ultra Centrifugation (AUC) 
AUC was carried out in a Beckman Coulter ProteomeLab XL-A analytical 
ultracentrifuge using standard 2 sector cells with quartz windows in 4- or 8-hole 
rotors. All sedimentation velocity experiments were at 50,000 rpm with a preset 
scan number of 100 per cell. The reference sector was filled with 450 µL of buffer 
(50 mM MOPS, .15 M NaCl, pH 7.4) and the sample sector was filled with 430 µL of 
sample with an absorbance at 412 nm (1 cm path length) between 0.75 and 1.1. 
Buffer density (1.00718 g/mL) was measured at 20.0 C in a Mettler/Paar 
Calculating Density Meter DMA 55A and buffer viscosity (0.010543 Poise) was 
measured in an Anton Parr AMVn Automated Microviscometer. A partial specific 
volume of 0.746 mL/g for bovine hemoglobin was used in calculating molecular 
weight (DeMoll et al. 2007). Data were analyzed using the program Sedfit 
(www.sedfit.com). Molecular weights and sedimentation coefficients were 
determined using the continuous c(s) mode in the sedfit program. Native tetrameric 
hemoglobin yielded an s20,w value of 4.25 S which agrees with the accepted value 
(Field and O'Brien 1955). The c(s) plots were deconvoluted using nonlinear least-
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squares fitting algorithms available in the Origin (v. 9.0) software package 
(OriginLab Corporation, Northapmton, MA).  Data were fit to multiple Gaussian 
components, increasing the number of components until residual plots (data-fit) 
were random and the chi square value for the fit was minimal. 
Circular Dichrosim (CD) Secondary Structure characterization of PEG XL-Hb 
Circular Dichroism (CD) experiments were carried out on an OLIS DSM 20 CD 
Hummingbird Spectrophotometer. Water used to collect base line data was also 
used as the dilution solvent for the Hb samples. For each sample a wavelength range 
of 180-280 nm was monitored and one data point per nm was collected while 
integration time was a function of high volts. The spectra were then smoothed using 
Solvitsky Golay 11 point (Whitmore and Wallace 2004; Whitmore and Wallace 
2008). 
Thermal Denaturation Procedure 
 Experiments were conducted according to Olsen’s protocol (Olsen 1994). 
Experiments were conducted in 10 mM MOPS, 0.9 M guanidine HCl pH 7.0. Samples 
were prepared so that the absorbance at 409 nm was between 1 and 1.2. Samples 
were monitored every minute on an Agilent 8453 spectrophotometer. A 
temperature increase of 0.3C/ min was controlled by Neslab Endocal, Temperature 
Programmer ETP-3, and Digital Controller/Readout DCR-4. Absorbance versus 
temperature was plotted and the fraction denatured was determined by the 
equation FD = (A-AN) / (AD-AN) where A is experimental absorbance, AN is 
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absorbance of native protein, and AD is absorbance of denatured protein. AN and AD 
were determined by fitting a linear line to the portion of the absorbance versus 
temperature plot that corresponded to the effect of temperature on the native or 
denatured spectrum respectively. The curve of FD versus temperature was 
smoothed in Microsoft Excel. 
Autoxidation Experiments 
 Autoxidation of native, crosslinked, and PEG crosslinked hemoglobin was 
carried out according to Yang and Olsen (Yang and Olsen 1989). Hemoglobin 
samples were fully reduced and dialyzed in 10 mM MOPS, pH 7.0. Sodium cyanide 
was added to each sample and allowed to equilibrate at room temperature for five 
minutes prior to data collection. The experiments were conducted at 37C and 
allowed to equilibrate before spectra were recorded from 500-700 nm on an Agilent 
8453 spectrophotometer. 
Oxygen Binding and Determination of P50 and Hill Coefficients 
 The samples, fully reduced with dithionite, were added to 4.0 mL of 10 mM 
MOPS, pH 7.4 and 10 L of Hemox Antifoam and equilibrated to 37 C. Oxygen 
binding was determined using a HEMOX Analyzer for native bovine Hb, native Hb 
with IHP, XL-Hb, XL-Hb with IHP, and PEG XL-Hb. Hill coefficients (n) and 
oxygen affinity (P50) were obtained from Hill plots. 
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Results 
Crosslinked Hemoglobin (XL-Hb) Production and Purification 
Presence of XL-Hb product was verified by SDS-PAGE that showed distinct, 
equal intensity bands around 14.4 kDa and 30.0 kDa (Figure 23). The band at 30.0 
kDa was indicative of the α monomers covalently linked together by DBSF under 
deoxy-conditions while the band at 14.4 kDa was representative of the β monomers. 
Confirmation of Large Molecular Weight Species and Separation of PEG XL-Hb from 
Unreacted XL-Hb 
Figure 23 is the SDS-PAGE gel of the purified PEG XL-Hb sample with a new 
band at the origin of the gel. The presence of this band confirmed large molecular 
weight species. Figure 24 is a S-300 normalized chromatogram, while Figure 25 is a 
chromatogram of the first peak of the S-300 column on a S-500 column. This two 
phase separatory system did not resolve the different PEG αXL-Hb species. There 
was a noticable separation between the PEGylated and unreacted species. Protein 
standards were run, and the elution volume of the PEGylated species resembled that 
of apoferritin (MW= 443 kDa) (Fig. 25). The elution volume of the product was used 
in tandem with an experimental standard curve that gave a calculated apparent 
molecular weight of ~ 500 kDa. This value correlates to a product that has 7 Hb : 1 
PEG backbone. Regardless of the DIBO : Hb activation ratio, there were no 
differences in the elution volumes of the product. 
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Figure 23. SDS-PAGE results of αXL-Hb and PEG αXL-Hb. The αXL-Hb shows 
characteristic bands at both 14.4 kDa (β monomers) and 30.0 kDa (XL α monomers). 
PEG αXL-Hb shows the same characteristic bands along with the presence of a dark 
band at the origin of the gel. Presence of the 14.4 and 30.0 kDa bands in the 
PEGylated sample indicate that the activation of Hb via DIBO-NHS and subsequent 
PEGylation do not show specificity towards either the α or β monomers of Hb, a 
consequence of the high amount of exposed Lys residues. 
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Figure 24. S-300 normalized chromatogram. Unreacted XL-Hb eluted around 75 
mL while the larger PEG XL-Hb product eluted between 40 and 60 mL. 
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Figure 25. An overlay of the chromatograms from S-500 SEC of PEG αXL-Hb (Red), 
unreacted αXL-Hb (Blue) and two standards, apoferritin (Black) and thyroglobulin 
(Green). An elution volume of 220 mL represents the PEG αXL-Hb sample while an 
elution volume of 250 mL is seen for the αXL-Hb sample. A large amount of the 
PEGylated product has an apparent molecular weight similar to apoferritin (MW of 
443 kDa). However, the broad shouldering on the front side of the column could be 
resultant of larger MW species whose apparent weight is lower than that of 
thyroglobulin (MW 669 kDa). 
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Size Determination of PEG XL-Hb Samples via Analytical Ultracentrifugation (AUC) 
The samples from the S-500 SEC column were analyzed by AUC. Figure 26A 
shows three separately prepared samples with a 1:1 DIBO to Hb activation ratio 
while Figure 26B is a deconvolution of one of the data sets. It was found that there 
were three major high molecular weight PEGylated species. The predominant 
species appeared to contain 3-4 Hb tetramers per PEG. Figure 27A shows three 
separate PEG αXL-Hb samples that were prepared with a 2:1 DIBO to Hb activation 
ratio. The samples were reproducible in their heterogeneity even more so than the 
1:1 activation. Figure 27B is a deconvolution of one of the samples. It was found that 
there were four large molecular weight PEGylated species, with the predominant 
one being 3-4 αXL-Hb tetramers per PEG.   
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CD Analysis of Secondary Structure in PEG XL-Hb 
CD analysis of the Hb samples showed characteristic signals for alpha helical 
secondary structure (Fig 28). The presence of the crosslinker in the central cavity or 
a PEG backbone attached to the tetramer did not disrupt the secondary structure. 
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Thermal Denaturation of Hb Samples 
 Comparison of the fraction denatured curves is shown in Figure 29. The 
melting temperatures (Tm) can be found in Table 5. Crosslinking stabilizes the 
tetramer compared to native Hb while PEGylation decreases the stability of the 
crosslinked species. Experimentally determined Tm values were found to be 
statistically significant in their differences through a single factor ANOVA. 
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Autoxidation of Hb Samples 
 Autoxidation expermients were conducted at 37C to see the effects of 
crosslinking and PEGylation on the autoxidation rates at physiological 
temperatures. Table 5 contains the relative rate constants (krel) of autoxidation. The 
relative rate constants were determined by dividing the slopes of methemoglobin 
production for XL-Hb and PEG XL-Hb by the slope of native Hb. It was 
determined that crosslinking increased Hb autoxidation rate by 1.78 times and 
PEGylation further increased the autoxidative rate to 2.39 times that of native Hb. 
Figure 30 shows the spectral changes observed in the PEGylated Hb sample. There 
was a decrease in the oxyhemoglobin absorbance at 540 and 576 nm as the sample 
autoxidized. 
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Figure 30. Autoxidation and spectral changes in PEG XL-Hb sample. The spectra 
showed a decrease in absorbance at 576 and 540 nm and an increase of absorbance 
at 630 and 510 nm as the sample was allowed to oxidize. 
 
Oxygen Binding Determination of Hb Samples 
Figure 31 shows the oxygen binding curves for the three Hb samples. Table 5 
presents the experimental P50 values and Hill coefficients (n) that were determined 
for native Hb, XL-Hb, and PEG XL-Hb. It was found that XL-Hb had a P50 similar 
to that of native Hb within a RBC (P50=27.57). PEG XL-Hb had a slightly lower 
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oxygen affinity than XL-Hb with a P50 of 31.97. The difference between the two was 
negligible suggesting that inside-out PEGylation did not further affect the oxygen 
affinity of XL-Hb. Table 5 also shows that upon crosslinking there was a decrease 
in cooperativity as demonstrated by the reduced Hill coefficient. However, 
PEGylation did not significantly lower n any further. 
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Table 5. Experimentally determined Tm (C) from fraction denatured curves, relative 
rates of autoxidation at 37C (krel), and P50 (torr) and Hill Coefficients determined at 
37C for native bovine Hb, αXL-Hb, and PEG αXL-Hb. 
 
Sample Tm (°C)* krel P50 (torr) Hill Coefficient (n) 
Native Hb 41.3 ± .9 1 11.25 ± .17 2.91 ± .06 
XL-Hb 53.5 ± .7 1.78 ± .33 27.57 ± 1.36 1.39 ± .01 
PEG XL-Hb 46.1 ± .7 2.39 ± .34 31.97 ± 4.48 1.26 ± .04 
*ANOVA (F=200.3, Fcrit=5.1) 
 
Discussion  
A large inside-out PEG Hb polymer was successfully produced by modifying 
exposed Lys residues with a cyclic strained alkyne and PEGylated through copper 
free azide-alkyne click chemistry. SDS-PAGE verified crosslinking and PEGylation of 
the Hb species (Figure 23).  In the XL-Hb sample, the band at 14.4 kDa is the non-
crosslinked  subunits while the 30.0 kDa band is the covalently crosslinked  
subunits. These bands were still present in the PEGylated sample with the 
concurrent presence of a new band at the origin of the gel. This indicates that the 
activation of Hb via DIBO-NHS and subsequent PEGylation does not occur on only 
one subunit. This is resultant from the high amount of exposed Lys residues in 
bovine Hb. However, the -XL band appears to be lighter in intensity indicating a 
slightly higher affinity for modification on the  subunits compared to the  
subunits. It has been previously reported that there are four Lys residues on the  
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and  subunits commonly PEGylated; but by contrast, there is a higher affinity for 
the  subunits by comparison (Li et al. 2008). 
Large Hb polymers have been found to attenuate stroma free Hb’s 
vasoconstrictive properties (Harrington and Wollocko 2011; Martini et al. 2006; 
Matheson et al. 2002; Palmer 2006; Palmer and Intaglietta 2014). This is achieved 
through increases in the molecular radius and/or hydrodynamic volume. These size 
alterations restrict the polymer’s ability to come in contact with the endothelial 
lining, as seen in prior, large, non-vasoactive Hb particles (Matheson et al. 2002). 
PEG is known to be especially efficacious in achieving these effects. This is resultant 
from its highly hydrophilic nature and capacity to bind multiple water molecules per 
repeating PEG unit (Hu et al. 2005). A nine-fold increase in hydrodynamic volume 
and two-fold increase in molecular radius of PEGylated proteins has been observed 
and is not uncommon (Meng et al. 2014; Wang et al. 2014). Inside-out PEGylation 
was used to produce such a Hb polymer. Size determination and characterization 
were achieved through a two-phase SEC followed by AUC. Separation of XL-Hb and 
PEG XL-Hb was observed with S-500 SEC but resolution of the polymeric species 
was not seen (Fig. 25). Regardless of DIBO : Hb activation ratios, there were no 
differences observed in elution volumes. Furthermore, the elution volume was 
identical to that of previously reported inside-out PEGylated proteins generated by 
thiol-maleimide click chemistry (Chapter 3). Figure 25 shows the chromatogram of 
PEG XL-Hb and known protein standards. The elution volume of the PEGylated 
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species resembled that of apoferritin (MW= 443 kDa). According to S-500 SEC, this 
molecular weight corresponds to a product that has ~7 Hb : 1 PEG backbone. 
However, this is not an accurate representation of the molecular weight but rather 
the apparent molecular weight of the polymer in solution. PEG has been shown to 
increase a proteins hydrodynamic volume up to nine fold as a result of the PEG’s 
ability to retain two to three water molecules per repeating unit (Hu et al. 2005). As 
expected, PEGylated proteins appear larger than non-PEGylated standards. 
AUC was used to characterize the molecular weight and product speciation. It 
was found that PEG XL-Hb generated with a 1:1 DIBO-NHS : Hb molecular ratio 
had three predominant large molecular weight species ranging from 3 to 6 αXL-Hb 
per PEG backbone (Figure 26). The broad peak in Figure 26B shows the difficulty in 
delineating between some of the larger polymers. The major product is around 4 Hb 
: 1 PEG backbone. Production of PEG XL-Hb with a 2:1 DIBO-NHS : Hb (Fig. 27) 
showed four large molecular weight species ranging from 3 to 8 αXL-Hb tetramers 
per PEG backbone with the predominant species being 4 Hb : 1 PEG backbone 
(Figure 27B). Comparison of the two samples (Figure 26 and 27) shows that the 1:1 
activation produces less speciation than the 2:1 activation but reproducibility in 
heterogeneity amongst samples is nearly identical in the 2:1 sample. Moreover, AUC 
data for the 2:1 activated product looked similar to prior inside-out PEGylated 
polyHb (Chapter 3). Prior inside-out PEGylated polyHb polymers utilized the only 
two Cys residues, Cys 93, to conjugate a  XL-Hb tetramer onto the PEG backbone. 
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With the same number of reactive sites to PEGylate compared to the previous 
method, it was expected that azide-alkyne inside-out PEGylation would look similar. 
However, the predominant species is 4 Hb : 1 PEG, one tetramer more than prior 
products (Chapter 3). Figure 32 is a schematic representation of the major PEG XL-
Hb product. It has been found that larger Hb polymers are unable to scavenge NO in 
vivo because they cannot get close enough to the endothelial lining making a larger 
Hb nanoparticle more desirable (Matheson et al. 2002; Palmer 2006). Furthermore, 
oncotic pressure is relative to the number of particles in solution than the molecular 
weights of said components. Thus, larger Hb particles have the potential to reduce 
harmful changes in pressor activity upon administration.  
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Figure 32. Proposed schematic of Inside-out PEGylated crosslinked hemoglobin. It is 
more probable that two arms will bind to a single tetramer than one arm binding to 
an individual tetramer. The major inside-out PEGylated hemoglobin polymer 
species produced is depicted above (4 Hb : 1 PEG). 
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Shown here, inside-out PEG XL-Hb can be classified as both a dendremeric 
and poly Hb structure (Kluger and Zhang 2003). In the past poly hemoglobins have 
been produced via azide-alkyne copper mediated click chemistry (Foot, Lui, Kluger 
2009; Singh et al. 2015b; Yang and Kluger 2010). Conversely, this is the first poly Hb 
to be generated without using copper mediation, but rather a cyclic strained alkyne. 
With the reaction allowing to proceed without copper, there is no concern of 
contamination of the product with an undesirable metal. Other polymeric dimers, 
trimers, and octamers of Hb have been generated under different conditions. These 
have been created by both chemical modifications and genetic mutations to the Hb 
tetramer (Bobofchak et al. 2003; Fablet et al. 2003; Faggiano et al. 2011; Fronticelli 
et al. 2001; Vasseur-Godbillon et al. 2006). One of the largest poylmers was around 
500 kDa and was shown to not adversly affect blood pressure upon comparision to 
crosslinked Hb (Bobofchak et al. 2003). It was infered that this was a result of 
decreased extravasation of the compound in circulation. Unfortunately, the 
limitations in these approaches are in the amount of genetic mutations and/or 
chemical synthesis required to create said products. Cyclic strained mediated azide-
alkyne inside-out PEGylation makes similar sized Hb polymers with commercially 
available reagents. Moreover, the methods presented here can be easily translated 
to use for other proteins. 
Stroma free Hb dissociates into  dimers in circulation which is readily 
filtered out by the kidneys and highly nephrotoxic. Dissociation of the tetramer is 
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thus circumvented through crosslinking (White and Olsen 1987). The fraction 
denatured curves (Figure 29) show that this modification also increases protein 
stability. The melting temperature for XL-Hb has been previously reported and 
agrees with the experimentaly determend value presented in this paper (Tm = 53.5 
C) (Olsen 1994; White and Olsen 1987; Yang and Olsen 1991). Upon PEGylation, 
the stability of the tetramer decreases (Tm =  46.1 C) but is still more stable than 
stroma free Hb (Tm = 41.3 C). The observed decrease in Tm was also seen in ealier 
inside-out PEGylated Hb polymers (Chapter 3) indicating that crosslinking plays a 
larger role affecting Hb properties than PEGylation.   
Autoxidation experiments were carried out to assess the speed at which the 
Hb samples oxidized at biological temperatures. Within a RBC is a naturally 
reducing environment that helps maintain Hb in the functional Fe 2+ state. Upon 
extraction from the RBC, Hb more readily oxidizes to the Fe 3+ state. Former studies 
have found that crosslinking under deoxy conditions increase the rate of 
autoxidation (Yang and Olsen 1989). The data here agrees with those findings and 
XL-Hb oxidizes 1.78 times faster than that of stroma free Hb (krel). Following 
PEGylation, the rate of oxidation increases to 2.39 times faster than that of stroma 
free Hb (Table 5). Figure 30 shows the characteristic spectral changes of the 
PEGylated sample as it was allowed to oxidize. Previous studies have shown this 
trend in oxidation rates. Acharya and colleagues have previously shown that 
PEGylated Hb species oxidize two to three times faster than their unmodified 
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counterparts (Hu et al. 2008). The increase in krel to PEGylated species has been 
attributed to PEGs water rich nature. When PEG sequesters water molecules it 
brings them into closer proximity of the Hb tetramer and allows for an increase in 
water mediated oxidation of the iron center. However, when the magnitude of 
change is compared following the progression of protein modification, PEGylation 
does not increase krel as much as crosslinking. Stroma free Hb to XL-Hb shows an 
increased rate of oxidation by 78%, where XL-Hb to PEG XL-Hb shows an 
increase of 61% (Table 5). Consequently, the rate of oxidation is affected more so by 
crosslinking than modification of the Lys residue and subsequent PEGylation. 
Fortunately, it is speculated that the increased rate of oxidation seen at 37 C in vitro 
will be less compared to that in vivo due to the antioxidant agents present within 
plasma (Hu et al. 2008; Snyder et al. 1987; Yang and Olsen 1989).       
 Crosslinking not only affects the stability of the Hb tetramer but also oxygen 
affinity. Similar CD spectra between Hb samples (Figure 28) elucidated that 
differences in oxygen affinity are not correlated with changes in secondary structure 
but rather crosslinking protocol. Oxygen binding studies determined that azide-
alkyne mediated inside-out PEGylation does not influence the oxygen affinity of Hb. 
The P50 values (Table 5) show that the crosslinking methodology dictates the 
capacity for Hb to bind and release oxygen (PEG XL-Hb P50 = 31.97 torr, XL-Hb 
P50 = 27.57 torr). This has been observed in past inside-out PEGylated Hb samples 
and is novel to this form of PEGylation (Chapter 3).  Traditional PEGylated Hb 
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polymers that coat the exterior of Hb with multiple PEG chains have been shown to 
increase oxygen affinity independent of PEGylation methodology (Hu et al. 2007; Li 
et al. 2008; Li et al. 2009; Lui et al. 2012). Addition of IHP, a 2,3-BPG mimetic, shifted 
the oxygen binding curve to the right in all the samples (Walder et al. 1979; Walder, 
Walder, Arnone 1980). A shift that lowers oxygen affinity has been previously 
reported for XL-Hb and shows that the compound is still accesable to Hb in the 
PEGylated product. Decreases in experimentally determined Hill coefficients were 
observed post crosslinking and following PEGylation. Cooperativity is reduced if Hb 
loses its ability to rotate freely when converting from T to R state upon binding 
oxygen. Crosslinking adds a covalent linker in the central cavity restricting the 
tetramers rotation, and thus reducing the experimentally determined n seen in 
Table 5 (Hb = 2.91, XL-Hb = 1.39). Covalently binding PEG to the XL tetramer 
further resticts movement and slightly decreases the cooperativity (PEG XL-Hb n = 
1.26). However, this decrease does not affect the oxygen delivery capabilities of the 
product. The experimentally determined P50 values of the XL-Hb and PEG XL-Hb 
are similar to that of Hb in a RBC. Thus, it is expected that PEG XL-Hb will deliver 
oxygen in a nondiscriminatory manner.     
Conclusion 
We have successfully produced a second inside-out PEGylated Hb complex 
through a different combination of crosslinking and PEGylation protocols. 
Concurrent application of crosslinking and inside-out PEGylation have the potential 
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to mitigate problems seen in previous HBOCs. The oxygen affinity of the product is 
similar to that of Hb within a RBC. In addition, this method produced a larger 
polymer in comparison to that of thiol-maleimide inside-out PEGylation (Chapter 3). 
In theory, the polymer should be able to deliver more oxygen per particle than the 
PEG XL-Hb product. With an extra Hb tetramer, on average, covalently linked to the 
PEG backbone per particle allows for a higher amount of oxygen to be delivered to 
the tissues. Inside-out PEGylation has applications past HBOC development. We 
have provided another way to engineer large protein complexes, without the need 
for traditional CuAAC. The results reported here promote the versatility that multi-
arm inside-out PEGylation possesses. Inside-out PEGylation is not restricted to one 
method of click chemistry or to a specific protein. We believe that this method of 
PEGylation will be effective in the synthesis of other biomacromolecules. 
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CHAPTER V 
FUTURE WORK AND CONCLUSIONS 
Future Work 
To determine the efficacy of the inside-out PEGylated Hbs as HBOCs, cell 
cultures, and/or animal studies need to be conducted. Often, after product 
generation and characterization of a new HBOC, animal studies are conducted. 
However, cell studies may be more appropriate before testing on an entire 
organism. Animal studies are costly and require an immense amount of product. 
Before identifying if the product delivers oxygen and/or produces ROS in vivo, it 
should be determined whether or not an immune response will be elicited. Ideally, 
the first avenue for research to determine this is through cell cultures. In the past 
these have not been readily utilized to characterize HBOC products, except a few 
that used immunological cells and tissues. These experiments looked at immune 
responses induced by the production of cytokines interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-) (Zhu et al. 2011). IL-6 is a pro-inflammatory cytokine 
and anti-inflammatory myokine, where TNF- stimulates inflammation, apoptotic 
cell death, and fever. These cytokines are expressed in myocardial tissue and can be 
monitored and quantified with the use of ELISA. If an immune response is 
generated, the product will do more harm than good. This can easily be identified 
prior to animal studies through this technique. 
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In addition, cell studies with HeLa cells should be looked into to evaluate the 
products safety prior to animal studies. Cell studies of this nature have not been 
utilized in the past to characterize HBOC products. It is my belief that it should be 
another standard practice prior to animal studies. This study would be able to 
identify if the product will induce cell death, possibly from ROS production. 
Furthermore, these studies can be conducted under normoxic and hypoxic 
conditions, evaluating any changes in oxygen levels that may be seen in vivo.  
Finally, animal studies should be carried out to evaluate HBOC efficacy. This 
is usually done by draining blood from the animal, inducing hemorrhagic shock, 
then infusing the animal with the HBOC product (Cabrales et al. 2005; Cabrales 
2010; Cabrales et al. 2010; Conover et al. 1997; Matsumoto et al. 2005; Raat 2005). 
Upon administration, short and long term effects can be monitored. Short term, 
damage to the cardiac and vascular tissue can be monitored while examining oxygen 
deliver. If the animal is kept alive for longitudinal studies monitor post operatory 
conditions such as vascular resistance, kidney damage, gastrointestinal damage, and 
recovery times. While these are the first major steps in evaluating human efficacy, it 
should be followed by the aforementioned experiments and build upon them.       
Conclusions 
Presented here are two different inside-out PEGylated Hb polymers that 
show potential as blood substitutes. We have shown that this form of PEGylation is 
not restricted by the method of conjugation chemistry as seen by its success with 
thiol-maleimide and azide-alkyne click chemistry. Inside-out PEGylation does not 
alter the secondary structure of the protein while making it more stable by 
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comparison to the unmodified protein. Although the products are heterogeneous, 
their heterogeneity is reproducible amongst sample preparations. Both products are 
large enough in size where they should not be able to interact deleteriously in 
circulation with endothelial tissue. However, each product has very different oxygen 
delivery characteristics. The PEG XL-Hb sample would release oxygen to highly 
hypoxic tissue where a PEG XL-Hb would deliver oxygen in a non-discriminatory 
fashion, similar to that of Hb in RBCs. 
A viable alternative to current blood transfusions has been actively pursued 
for several decades with minimal success. A limited supply of blood, dependent on 
human donors, has demanded the creation of a hemoglobin-based oxygen carrier 
(HBOC) from non-human sources. Such a product would deliver oxygen to tissues, 
providing a therapeutic response to hemorrhagic trauma. However, an effective 
HBOC has a utility that exceeds applications in hemorrhagic shock responses.  It 
may also be used to treat carbon monoxide poisoning, acute anemia, organ ischemia, 
and cardioplegia—all conditions related to oxygen deprivation. With a myriad of 
potential applications, my research is centered on alleviating the dependence on 
human blood donations. 
 Blood donations must be tested for blood borne pathogens such as HIV. In 
The United States of America and other developed countries, testing is not 
exceedingly taxing but does take time and decrease the potential pool for donations. 
However, in less developed countries where money and testing supplies are limited, 
the necessity of a sustainable alternative to blood donations that is disease free 
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cannot be understated. Countries where HIV is more predominant already have a 
diminished pool to draw on for donations and our product would hopefully be able 
to supplement the donations, and most importantly, be produced at a minimal cost. 
The research maintains the idea that for the product to be viable from a production 
standpoint, it must be relatively simple and inexpensive to produce. The chemistry 
used herein to create potential HBOCs is affordable and generated from 
commercially available reagents that can be scaled up for mass production.  
 In addition to the aforementioned reasons to produce a blood substitute, the 
product will ideally ameliorate the need for mass blood donations in times of 
natural disasters or crisis. When such a disaster occurs that leads to a large 
population in need of blood transfusions, our product would be available in a supply 
greater than the available—and finite—supply of current blood transfusions. My 
work has the potential to provide the global community with the therapeutic 
potential to respond liberally to hemorrhagic trauma and other conditions of oxygen 
deprivation. The short and long term goals of the project address the viability of this 
HBOC, making it a truly successful product, focusing on both efficacy and practicality 
of production. Such a substitute has the potential to fill a great need in human health 
and bridge an economic divide to the costly alternative treatments that are 
currently available. 
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